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Summary 
Regulatory T cells (Tregs) are a CD4+ T cell subset, which maintains tolerance 
towards self and harmless foreign antigens and is characterized by expression of the 
master transcription factor Foxp3. Besides this well studied Treg-specific feature, 
several effector molecules have been identified as preferentially but not exclusively 
expressed in Tregs. Activation via the T cell receptor (TCR) is crucial for T cell 
functionality, and there is accumulating evidence that TCR signaling is differentially 
organized in Tregs as compared to their counterparts, conventional T cells (Tconv). 
Accordingly, formation and composition of the immunological synapse (IS), built at 
the interface of interacting immune cells, differs between Tregs and Tconv. 
Quantitative phosphopeptide sequencing of Tregs and Tconv, which was recently 
performed in our laboratory, revealed a pre-activated phenotype of Tregs as 
compared to Tconv and identified differentially regulated phosphorylation sites 
between the two T cell subsets. Those might serve as promising candidates for 
targeted intervention of Treg activation. 
The present study (i) addressed the functional role of Themis, which is strongly 
under-represented in Tregs, for their suppressive capacity. Furthermore, in order to 
expand current knowledge about differential TCR signaling in Tregs and Tconv, (ii) 
phosphorylation kinetics of selected sites were performed. (iii) The functional impact 
of a novel phosphorylation site at Y523 of CalDAG GEFI (Calcium and DAG 
regulated guanine nucleotide exchange factor I), which was identified via the 
aforementioned phosphoproteomic approach, and (iv) the role of the protein itself for 
development and function of Tregs was investigated. 
In summary, selective targeting of Tregs by intervention at the signaling level 
might serve as promising future therapeutic strategy. Up to date, the major obstacle 
is the lack of specific tools, both to investigate intracellular signaling at the bench and 
to target selected signaling processes cell subset-specifically at the bedside. 
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Zusammenfassung 
Regulatorische T-Zellen (Treg-Zellen) sind ein Teil der CD4+ T-Zellen und 
dienen der immunologischen Toleranz gegenüber “Selbst” und harmlosen 
Fremdantigenen. Das Hauptcharakteristikum von Treg-Zellen ist die Expression des 
bereits eingehend untersuchten Transkriptionsfaktors Foxp3. Neben Foxp3 wurden 
weitere Effektormoleküle identifiziert, die zwar vorwiegend, aber nicht ausschließlich 
von Treg-Zellen exprimiert werden, und daher nur bedingt der Unterscheidung von 
Treg-Zellen und konventionellen T-Zellen (Tconv-Zellen) dienen. Die Aktivierung über 
den T-Zellrezeptor (TCR) ist entscheidend  für die Funktion aller T-Zellen, und es 
wird zunehmend deutlich, dass der intrazelluläre TCR Signalweg von Treg-Zellen 
und Tconv-Zellen divergent reguliert ist. Dementsprechend unterscheiden sich auch 
Formierung und Zusammensetzung der immunologischen Synapse, der 
Kontaktfläche zwischen interagierenden immunologischen Zellen, zwischen 
Treg- und Tconv-Zellen. Eine quantitative Bestimmung phosphorylierter Proteine 
beider T-Zellsorten, welche kürzlich in unserem Labor durchgeführt wurde, 
identifizierte diverse differentiell regulierte Phosphorylierungsstellen, welche 
vielversprechende Kandidaten zur spezifischen Intervention der Treg-Zell-Aktivierung 
darstellen. 
In der vorliegenden Arbeit wurde (i) die funktionelle Rolle von Themis, einem 
Protein mit geringerer Expression in Treg- als Tconv-Zellen, für den suppressiven 
Phänotyp von Treg-Zellen untersucht. Um die Identifizierung differentiell 
phosphorylierter Proteine voranzubringen, wurden (ii) Kinetiken ausgewählter 
Phosphorylierungsstellen generiert. Außerdem wurde (iii) die Funktion einer 
Phosphorylierung des Proteins CalDAG GEFI (Calcium and DAG regulated guanine 
nucleotide exchange factor I) untersucht und (iv) die generelle Rolle dieses Proteins 
in Treg-Zellen analysiert. 
Zusammenfassend stellt ein gezieltes Eingreifen in Treg-Zell-spezifische 
Signalwege eine vielversprechende Möglichkeit für zukünftige Therapiestrategien 
dar. Bisher ist hierbei das Fehlen spezifischer Hilfsmittel zur erfolgreichen 
Erforschung und zielgerichteten Adressierung der T-Zell-Signaltransduktion die 
größte Hürde.  
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1. Introduction 
1.1 Innate and adaptive immunity at a glance 
Vertebrate organisms have developed strategies to protect themselves from 
invading, potentially harmful, entities. As a quick but rather unspecific line of defense, 
innate immunity comes into play with a variety of immune cells such as macrophages 
and neutrophils, which recognize pathogen-associated molecular patterns (PAMPs) 
[1] via their pattern recognition receptors (PRRs) [2, 3]. PRR activation triggers innate 
immune cells to secret cytokines, which in turn kick-start an inflammatory response to 
directly attack the pathogen and simultaneously activate the second arm of the 
immune system, adaptive immunity [4]. A key linker between innate and adaptive 
immunity are professional antigen-presenting cells (APCs), including different 
subsets of dendritic cells (DCs) [5]. DCs take up proteins from their surroundings, 
which are processed and finally linear peptides thereof are presented with the aid of 
the major histocompatibility complex (MHC) expressed on the DC surface [6]. 
Peptide-loaded MHCs (pMHC) are indispensable for antigen recognition by 
T lymphocytes, which represent one part of the adaptive immune system. The T cell 
receptor (TCR), which is constitutively attached to the T cell membrane, is restricted 
to antigen recognition specifically via pMHCs [7-10]. In contrast, the B cell receptor 
(BCR), which is expressed by the second main players of acquired immunity, namely 
B cells, recognizes three dimensional antigens [11]. The BCR can be secreted and 
acts in soluble form as antibody [10]. Both, BCR and TCR, are characterized by 
constant receptor domains and highly variable parts. Latter are generated by gene 
rearrangement, catalyzed by the enzymes recombination activating gene 1 or 2 
(Rag1 and Rag2), during lymphocyte development resulting in a unique BCR or TCR 
expressed on every B and T cell, respectively [12-14]. Importantly, DCs are not only 
presenting foreign peptides but also self-antigens. At the same time, TCRs are 
generated during the random TCR rearrangement, which are recognizing 
self-peptides. This bears the risk that self-reactive T cells encounter self-antigen 
presenting DCs, resulting in T cell activation and autoimmunity. To prevent this 
scenario, the immune system has developed several strategies: In the course of 
thymic T cell development, thymocytes bearing a self-reactive TCR are eliminated 
during a process called negative selection [15]. This process is partly mediated by 
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the transcription factor autoimmune regulator (Aire), which allows expression and 
subsequently presentation of self-peptides being specific for non-thymic tissues in the 
thymus to enable the development of tolerance towards peripheral tissues [16, 17]. 
Besides this mechanism to induce central tolerance, peripheral tolerance is 
generated by mature T lymphocytes in secondary lymphoid organs (SLOs) either by 
induction of anergy or mediated by specialized immunoregulatory cells. In case a 
self-peptide presenting DC encounters a self-reactive T cell that has escaped central 
tolerance, pMHC and TCR are matching but this cell interaction usually occurs in 
absence of an inflammatory environment. Due to the lack of pro-inflammatory 
cytokines, certain costimulatory molecules are not expressed by the APC and this 
absence of costimulation will drive the T cell into an anergic state [18]. Besides, up to 
now numerous immunoregulatory cells were identified, for example myeloid-derived 
suppressor cells (MDSCs), regulatory B and T cells (Bregs and Tregs, respectively), 
which actively suppress unwanted or overshooting immune responses by various 
mechanisms [19, 20]. In summary, the immune system of jawed vertebrates 
comprises two major branches: Fast, but rather short-lived and unspecific innate 
immune responses as well as long-lasting and memory-forming, very specific 
adaptive immunity. Both responses are complementary and need to be tightly 
controlled to avoid exceeding immunity and reactivity towards self and harmless 
antigens. 
1.2 T lymphocytes 
T cell precursors originate from hematopoietic stem cells (HSCs) in the bone 
marrow and migrate to the thymus for maturation. They enter the thymus as CD3- as 
well as co-receptor, CD4- and CD8- respectively, negative cells. CD3 is gradually 
upregulated during further developmental steps, the β chain of the TCR is 
rearranged, and the thymocytes express a pre-TCR consisting of a surrogate α chain 
and the rearranged β chain. Subsequently, both co-receptors are upregulated and 
Rag1/2-mediated rearrangement of the TCR α chain results in expression of a 
mature TCR. Now, thymocytes are first positively selected for bearing a TCR on their 
surface, which is capable of interacting with a MHC, and those T cells, which express 
a TCR that recognizes MHC-presented self-peptides with high affinity are negatively 
selected in a second step. Finally, double positive thymocytes will downregulate the 
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expression of either CD4 or CD8, and commit to one the two single positive T cell 
lineages [21]. CD4+ and CD8+ T cells that have undergone positive and negative 
selection leave the thymus and enter the periphery, where they constitute the naïve 
T cell pool. Upon encounter of their cognate antigen and costimulation provided by 
APCs, antigen-specific naïve T cells (Tnaive) undergo clonal expansion in order to 
give rise to sufficient numbers of T cells to mount an efficient immune response [22]. 
MHC class I-restricted CD8+ T cells develop into cytotoxic T lymphocytes (CTL), 
which for example eliminate cancer cells or cells infected by intracellular pathogens 
[23-28]. CD4+ T cells differentiate into helper T cells (Th), by upregulation of the 
subset-specific transcription factor and subsequent secretion of characteristic 
cytokines. Up to date, numerous T helper subsets were identified; however, the four 
major subsets are Th1, Th2, Th17 and Tregs. Th1 are characterized by the 
transcription factor T-box transcription factor (TBX21, T-bet) and secret interferon γ 
(IFNγ) [29, 30]. The master transcription factor of Th2 cells is Trans-acting 
T cell-specific transcription factor (Gata-3) and the Th2 subset produces interleukin-4 
(IL-4) [31-33]. Th17 cells secret IL-17 and are under control of the transcription factor 
RAR-related orphan receptor γ (RORγt) [34, 35]. The lineage-defining marker for 
Tregs is the master transcription factor Forkhead box protein p3 (Foxp3); Tregs are 
thoroughly introduced in the following paragraph. However, after shutdown of the 
immune response only a minor fraction of differentiated Th cells will convert to 
memory T cells, which can be rapidly re-activated by encounter of the same antigen, 
whereas the majority of effector T cells will be eliminated via apoptosis [36]. 
1.2.1 Regulatory T cells: Discovery and development 
Sakaguchi and colleagues were the first to show that depletion of CD4+CD5+ 
T cells leads to autoimmunity and that co-transfer of CD4+CD5+ T cells with 
CD4+CD5- T cells into immunodeficient mice preserves self-tolerance [37]. Another 
ten years later, the same group identified that the respective T cell populations are 
better distinguished by constitutive expression of the IL-2 receptor α chain (CD25), 
with CD4+CD25+ T cells having a suppressor-like phenotype as compared to 
CD4+CD25- conventional T cells (Tconv) [38]. Although CD25 expression serves as 
predominantly reliable Treg marker in the mouse system under homeostatic 
conditions, it cannot be used under inflammatory conditions as it is massively 
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upregulated upon T cell stimulation, especially by human T cells [39-42]. Therefore, 
discovery of the lineage-defining marker Foxp3 was a hallmark to the Treg field: The 
transcription factor Foxp3 is highly expressed in CD4+CD25+ T cells and ectopic 
expression of Foxp3 in CD4+CD25- T cells renders the cells suppressive. 
Additionally, Foxp3 expression identifies a CD4+CD25- T cell subset, which was also 
described to excert suppressive functions [43-47]. It was shown, that genetic 
disruption of the Foxp3 locus in mice causes fatal autoimmunity resulting in the scurfy 
phenotype and mutations in the Foxp3 gene in humans leads to development of the 
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) [48, 
49]. On the other hand, it was also reported that an excess of Tregs might support 
tumor growth and chronic infection establishment [50-54]. Foxp3 was shown to be 
the master transcription factor of Tregs, needed for generation of the cells, stability of 
the lineage and functionality [55-59]. A variety of Treg signature genes such as 
Glucocorticoid-induced TNFR-related protein (GITR, CD357), Cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA-4, CD152) and CD25 are regulated by 
Foxp3 [38, 60-62]. The Foxp3 locus itself is epigenetically modified in stable Tregs, 
manifested in the demethylation of the conserved non-coding sequence (CNS) 2, 
also referred to as Treg-specific demethylated region (TSDR) [63, 64]. 
Tregs develop both in the thymus as well as in the periphery in SLOs. CD4+ 
T cells with a TCR having a certain threshold of self-affinity can escape negative 
selection in the thymus and instead upregulate the transcription factor Foxp3 and 
commit to the Treg lineage [65, 66]. The expression of Foxp3 is either followed or 
preceded by upregulation of CD25, creating two Treg precursor subsets, 
CD25+Foxp3- or CD25-Foxp3+ [67, 68]. Tregs that are generated during T cell 
development in the thymus are referred to as thymus-derived Tregs (tTregs), and it 
was suggested that this cohort of Tregs is ensuring self-tissue integrity [69]. A second 
fraction of Tregs, peripherally-induced Tregs (pTregs), is generated from Tnaive 
when they recognize their cognate antigen presented by APCs in a tolerogenic 
environment and in presence of IL-2 and transforming growth factor β (TGF-β) [70-
72]. This second cohort of Tregs allows the establishment of tolerance towards 
harmless foreign antigens derived for example from commensal gut bacteria and 
nutrition [72-75]. Although several molecules were suggested to distinguish tTregs 
and pTregs such as Neuropilin-1 (Nrp1) and Helios, no reliable marker has been 
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identified so far because suggested molecules can be upregulated also by pTregs 
under inflammatory conditions [76-82].  
In vitro induced or expanded Tregs have been proposed for several therapeutic 
applications e.g. to augment allograft tolerance or treat allergy and autoimmune 
disorders. The major obstacle until now is the instability of transferred Tregs; the cells 
lose Foxp3 expression and might even turn pathogenic [83]. Therefore, considerable 
effort is put on the development of novel strategies to differentiate stable Tregs 
in vitro, with stability referring to methylation status of the TSDR. Several compounds 
have been tested for their potency to induce stable Tregs, e.g. retinoic acid and 
vitamin C [84-88]. Another approach is the identification of candidate genes that 
impact in vivo Treg generation, in order to manipulate in vitro generated Tregs on a 
genetic level. In contrast, as Tregs are known to be detrimental in cancer settings, 
molecular targets are quested to specifically interfere with Treg function in vivo [52]. 
1.2.2 Suppression mechanisms of Tregs 
A substantial number of studies has addressed and at least partly unraveled 
mechanistic modes of how Tregs promote suppression of unwanted or overshooting 
immunity. The identified approaches can be grouped into four distinct modes, which 
are all contact-dependent or at least mediated via close distance. Up to now, it is not 
fully understood whether every Treg is able to employ all of these mechanisms and 
how the cells decide which mode to use. It was suggested, that this decision is either 
made hierarchically or in a context-dependent manner [89]. 
It was shown that Tregs secrete inhibitory cytokines such as IL-10, IL-35 or 
TGF-β [90-95], and at least in case of IL-10, Tregs stimulate other cells to release 
anti-inflammatory cytokines [96]. Besides, Tregs are also capable of Granzyme A 
(GzmA, human Tregs), Granzyme B (GzmB, mouse Tregs) and perforin production, 
which cause pore formation in target cell membranes and ultimately results in 
apoptosis [97-101]. Another mode that leads to target cell death is via cytokine 
deprivation, as especially IL-2 is abundantly consumed by Tregs, as a result of the 
elevated expression levels of CD25 [102-104]. Transfer of cyclic AMP (cAMP), an 
inhibitory second messenger, through gap junctions or secretion of the ectoenzymes 
CD39 and CD73, which lead to generation of immunosuppressive adenosine, are 
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mechanisms to disrupt the target cell’s metabolism [105-107]. An indirect way to 
suppress effector T cells is via interference with DC function and maturation. Tregs 
express elevated levels of CTLA-4, which binds to APC-expressed CD80/86, 
removes the molecule from the DC surface via trogocytosis, and thus competes with 
CD28 for these shared ligands. As CTLA-4 displays higher affinity for CD80/86 as 
compared to CD28, ligand availability for Tconv to induce costimulatory signaling is 
reduced [108-111]. Additionally, interaction with Treg-expressed CTLA-4 stimulates 
DCs to secrete Indoleamine (2,3)-dioxygenase 1 (IDO), which in turn initiates the 
production of pre-apoptotic metabolites by effector T cells [61, 62, 112, 113]. 
Besides, Tregs are also interfering with intracellular signal transduction of immature 
DCs. Binding of Lymphocyte activation gene 3 protein (LAG-3), expressed by Tregs, 
to MHC class II on the DC surface, activates downstream signaling cascades that 
finally result in phosphatase activation and shutdown of immunostimulatory 
competence [114, 115]. This suppressive mechanism is also utilized by 
IL-10-secreting CD4+Foxp3- T cells [116]. 
1.3 Transcriptomics and proteomics of Tregs and Tconv 
Extensive effort was already made to unravel transcriptomic and proteomic 
signatures of Tregs and Tconv in order to uncover unique Treg features. Regarding 
transcriptomic information, a reasonable amount of data were collected and 
published in various databases (e.g. Immunological Genome Project, 
www.immgen.org). The very first transcriptomic comparison of Tregs versus Tconv, 
revealed differential expression of numerous genes in the two T cell subsets, and 
interestingly some of those, e.g. Helios, are Foxp3-independently regulated [117]. 
Foxp3-dependent transcriptional regulation was addressed by two parallel studies, 
and both came to the conclusion that Foxp3 can act as both activator and suppressor 
and that many of the Foxp3-dependent differentially regulated genes are connected 
to T cell activation [118, 119]. However, Hill et al. have challenged the view of Foxp3 
as a “Master regulator”, as their study found comparably little direct influence of 
Foxp3 on the Treg transcriptional landscape [120]. Transcriptomic approaches were 
intensified by the development of new sequencing methods, such as next generation 
sequencing, which added new insights to the existing knowledge [121]. Besides 
general comparisons of Tregs and Tconv, considerable effort was put to analyze 
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differences of Tregs from several tissues, revealing that the pool of peripheral Tregs 
found in SLOs is rather heterogeneous in terms of gene expression patterns [122]. 
Since then, numerous studies have addressed transcriptional profiles of Tregs from 
certain tissues or of genetically modified mice in the context of gene knockout or 
transgenic mice [123-126].  
Proteomic approaches are not as abundant so far, which can be mainly 
attributed to the higher need of input material for global proteomic analysis as 
compared to transcriptome analysis. The protein inventory of human Tregs and 
Tconv was addressed and thereby novel molecular players for Treg suppressive 
capacity, namely Galectin-10 and CD147, were identified [127, 128]. A more recent 
study by Procaccini et al. revealed differences in the metabolism of Tregs and Tconv, 
which showed that Tregs are predominantly relying on glycolysis to maintain their 
high proliferative capacity, whereas Tconv, which are less proliferative, utilize 
fatty-acid oxidation for energy supply [129]. Regarding energetic pathways, combined 
proteomic and phosphoproteomic profiling of resting and activated murine Tconv 
showed signaling and bioenergetic circuits that mediate the transition from T cell 
quiescence to activation [130]. Barra and colleagues published an extensive study 
comparing the proteome of ex vivo isolated Tregs and Tconv from spleen, lymph 
nodes (LNs) and thymus. They found transcription factor 7 (TCF7) significantly 
underrepresented in Tregs as compared to Tconv and were able to show a crucial 
role for lower TCF7 expression levels during tTreg development [131]. Recently, also 
our department performed a comparative proteome analysis of murine ex vivo 
isolated Tregs and Tconv [132]. Amongst others, we identified several histones to be 
differentially expressed as well as the proteins Niban, S100A4 and Themis 
(thymocyte-expressed molecule involved in selection). Niban was found at elevated 
protein levels in Tregs but so far there is no role for Niban described in T cells. 
S100A4, also upregulated in Tregs, is a member of the S100 family of Ca2+-binding 
proteins containing a characteristic EF-hand motif [133] and is mostly known for its 
metastasis promoting activity reported for various kinds of cancer. Besides cancer 
context, S100A4 was shown to be involved in directed granule release at the 
immunological synapse (IS) formed between natural killer (NK) cells and their target 
cells [134]. Additionally, a role for S100A4 in Th17-mediated rheumatoid arthritis by 
interference with intracellular signal transduction was described [135]. Themis was 
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one of the rare proteins that were underrepresented in Tregs as compared to Tconv. 
Themis localizes at the Linker for activation of T cells (LAT) signalosome due to 
interaction with Growth factor receptor-bound protein 2 (GRB2) and also interacts 
with Tyrosine-protein phosphatase non-receptor type 6 (PTPN6, SHP-1), and it was 
long time believed that thereby Themis is enhancing SHP-1 activity [136, 137]. Only 
recently it was shown that Themis directly interacts with SHP-1 via its 
“cysteine-containing all beta in Themis” (CABIT) domains and this interaction is 
strengthened by GRB2, but not absolutely dependent on GRB2. The CABIT domains 
interfere with phosphatase activity of SHP-1 through oxidation of a catalytically 
important cysteine residue in response to physiological reactive oxygen species 
(ROS) production. Thereby, Themis inhibits SHP-1 and indirectly enhances TCR 
signaling following low-affinity antigen binding during positive selection processes in 
the thymus [138]. With respect to Tregs, it was reported that Themis transcription is 
downregulated by Foxp3, which finally accounts for reduced Themis protein levels in 
Tregs as compared to Tconv [118, 132, 139]. Themis-/- mice show elevated Treg 
frequencies in the periphery, while absolute numbers were reduced by half as 
compared to wild type (WT) mice, which is explained by the generally reduced T cell 
compartment in Themis-/- mice [140]. Very recently, Duguet and colleagues found 
improved survival and slightly augmented in vivo suppressive capacity of 
Themis-overexpressing Tregs as compared to WT cells [139]. 
1.4 Dissimilar TCR signaling in Tregs and Tconv 
Both Tregs and Tconv require activation via the TCR in order to exert their 
respective effector functions [125, 126, 141, 142]. The TCR complex is a 
multi-protein machinery: The TCR itself is composed of either one TCRα and TCRβ 
chain or one TCRγ and TCRδ chain, and therefore specifies two major T cell subsets, 
αβ- or γδ-T cells, respectively. The TCR heterodimer is associated with one CD3δ 
and one CD3γ as well as two CD3ε and two CD3ζ chains, which enable intracellular 
signal transduction due to phosphorylation of the Immune-receptor-
Tyrosine-based-Activation-Motifs (ITAM). The TCR heterodimer recognizes pMHC on 
the surface of APCs, with CD4+ and CD8+ T cells being restricted to MHC class I and 
class II, respectively. Due to activation of the costimulatory molecules CD4 and CD8, 
Lymphocyte cell-specific protein-tyrosine kinase (Lck) is recruited to the TCR 
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signalosome and phosphorylates the ITAMs of CD3ζ. These serve as docking 
stations for 70 kDa zeta-chain associated protein (ZAP70), which is activated by 
phosphorylation upon binding. Subsequently, ZAP70 recruits and phosphorylates 
LAT, which leads to the formation of the LAT signalosome comprising PLCγ1 
(Phospholipase C-gamma-1), SLP-76 (SH2 domain-containing leukocyte protein of 
76 kDa), GRB2 and SOS1 (Son of sevenless homolog 1) amongst others. As 
described above, via GRB2, Themis is located at the LAT signalosome and directly 
interacts with SHP-1 [138]. PLCγ1 converts phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) into inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG) and 
consequently intracellular Ca2+ levels are increasing and numerous signaling 
cascades such as Ras/Raf (Rat Sarcoma/Rat Fibrosarcoma) and MEK/ERK1/2 
(Mitogen-activated protein ERK kinase/ extracellular signal-regulated kinase 1 and 2) 
pathways are initiated. Finally, this results in the activation and nucleus translocation 
of several transcription factors such as activator protein 1 (AP-1), nuclear factor of 
activated T cells (NFAT) and nuclear factor 'kappa-light-chain-enhancer' of activated 
B cells (NFκB) [143]. A nearly infinite number of costimulatory molecules have been 
identified, which can be broadly characterized as either activating or inhibitory. With 
regard to CD4+ T cells, one of the major costimulators is CD28, which is involved in 
tolerance induction. The CD28 ligands, CD80/86 are only expressed by APC in an 
inflammatory setting, and binding of CD28 to its ligands will trigger the T cell to be 
fully activated, differentiate and proliferate. It was shown that Tregs reduce their 
motility upon encounter with CD80/86-expressing APCs to induce sustained 
interaction [144]. In case, cognate antigen is detected by a T cell in absence of 
CD80/86 expression, the T cell becomes anergic or apoptotic [18, 145]. This scenario 
is utilized by Tregs to prevent Th cell activation and differentiation as described in 
section 1.2.2. Besides CD28, other activating costimulatory molecules are inducible 
costimulator (ICOS) and GITR, while inhibition is not only mediated via CTLA-4, but 
also by LAG-3 and programmed death-1 (PD-1), just to name a few [146-151]. 
Concurrent with T cell stimulation, integrin activation at the T cell surface takes place 
in order to support stable contacts to the APC, which also includes cytoskeletal 
reorganization. The entity of this whole signaling machinery close to the APC 
interaction site is termed the immunological synapse (IS) (Fig. 1). 
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Fig. 1: Proximal TCR signaling in Tregs. Schematic picture of TCR downstream signaling cascades 
towards initiation/termination of gene expression, cytoskeletal reorganization and integrin activation, 
details can be found in the text. Arrows between molecules depict direction of signal propagation. The 
immunological synapse is indicated in light blue and the guanine nucleotide exchange factor 
CalDAG GEFI, the protein in focus of this thesis, is highlighted by a red frame. Figure is modified from 
a kind courtesy of Lothar Jänsch and Marco van Ham (HZI, Braunschweig). 
 
There is growing body of evidence that TCR downstream signaling in Tregs is 
differentially organized as compared to Tconv [152]. Besides mere abundance of 
signalosome components as addressed by the above mentioned proteomic data 
[132], signaling processes itself differ with regards to the analyzed T cell subset. For 
example, Tregs exhibit reduced phosphorylation at S473 of AKT, and SHARPIN was 
identified to specifically control TCR signaling via ubiquitination processes in Tregs 
[153, 154]. Additionally, ERK1/2 activation downstream of TCR triggering as well as 
stimulation-induced Ca2+ flux are attenuated in Tregs [155-157]. Furthermore, TCR 
signalosome component recruitment is differentially organized in Tregs versus Tconv. 
It was shown by Zanin-Zhorov et al., that Protein kinase C theta type (PKCΘ) is 
located towards the IS in Tconv, but is sequestered away in Tregs, and the scaffold 
protein Disc large homolog 1 (Dlgh1) is highly accumulated specifically at the Treg-IS 
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[158, 159]. Multi-epitope Ligand Cartography (MELC) recently performed by our 
department, revealed diverging recruitment kinetics for various phosphorylated 
signalosome components in Tregs versus Tconv [132]. Furthermore, a couple of 
studies addressed abundance and activation of kinases in Tregs and Tconv. It was 
shown that the kinome of Tregs and Tconv differs and also the activation state of 
certain kinases varies following TCR activation in murine and human Tregs versus 
Tconv [160-162], also hinting towards differentially organized TCR signaling. Besides 
the aforementioned proteomic comparison of ex vivo isolated murine Tregs and 
Tconv, our group also performed quantitative phosphopeptide sequencing of resting 
and activated Tregs and Tconv, respectively. We found numerous phosphorylation 
sites at various proteins to be differentially phosphorylated when comparing resting 
Tregs and Tconv, as well as when comparing activated cells or resting against 
activated cells. Figure 2 summarizes the top 21 candidate proteins that show major 
regulation differences in the two examined T cell subsets. Displayed values are 
normalized to the phosphorylation state of resting Tconv. It is obvious that for many 
sites resting Tregs display a pre-activated phenotype, apparent from the elevated 
phosphorylation level. Whether the given phosphorylation level at the resting state is 
up- or downregulated upon stimulation is varying highly between the detected sites. 
Since a whole spectrum of signaling events was covered by this approach and taking 
into consideration the detected differential recruitment of phosphomolecules to the 
IS, it is tempting to hypothesize, that TCR ligation might lead to Treg- and 
Tconv-specific IS formation, respectively [132]. 
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1.5 Immunological synapse formation 
1.5.1 Structure and assembly of the IS 
The IS is a highly organized structure that is formed at the cell interface during 
interaction of T cells with APCs and was first described in 1998 by the laboratory of 
Abraham Kupfer [163]. It is composed of concentric rings, supramolecular activation 
clusters (SMACs), consisting of particular molecules implementing signal 
transduction and costimulation or cytoskeletal rearrangement and adhesion 
(Fig. 3A). The inner part, the central SMAC (cSMAC) accumulates TCR/pMHC 
microclusters and certain costimulatory molecules such as CD28. It is surrounded by 
the peripheral SMAC (pSMAC), which contains CD4 and intracellular signalosome 
components such as Lck; furthermore, the integrin Lymphocyte function-associated 
antigen 1 (LFA-1) is located within the pSMAC. The most outer ring, the distal SMAC 
(dSMAC) consists of filamentous actin (F-actin) and the tyrosine phosphatase CD45 
[163, 164]. Due to this unique structure, contrary signaling molecules are spatially 
separated, as for example TCR/pMHC microclusters including intracellularly 
phosphorylated ITAMs of CD3ζ and the phosphatase CD45. Additionally, involved 
molecules are organized according to size of their ectodomains to prevent steric 
Fig. 2: Phosphoproteomic analysis reveals 
differential signaling dynamics in primary murine 
Tconv and Tregs. Tconv and Tregs were 
FACS-sorted from pooled spleen and LNs from 
BALB/c mice as CD4
+
CD25
-
 and CD4
+
CD25
+
, 
respectively. Cells were either left unstimulated (0´) or 
stimulated via streptavidin-mediated crosslinking of 
biotinylated anti-CD3/28 for 5 min (5´). Samples were 
iTRAQ-labeled, enriched for phospho-peptides and 
analyzed via LC-MS/MS. The heatmap displays the 
21 phosphorylation sites, protein and respective site 
are named on the right, that were found to be most 
divergently regulated in Tconv (two columns on the 
left) versus Tregs (two columns on the right). All 
samples were normalized to the phosphorylation level 
of unstimulated Tconv (left column) and 
phosphorylation is depicted according to the color 
code given on top, with blue showing reduced 
phosphorylation and red depicting enhanced 
phosphorylation. Figure is a kind courtesy of Marco 
van Ham (HZI, Braunschweig). 
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hindrance [163, 165] (Fig. 3B). During IS assembly, recruitment processes follow a 
defined order and are strictly orchestrated. Upon pMHC recognition, TCR/pMHC 
microclusters are formed in the periphery of the contact zone aided by the actin 
cytoskeleton and are moved towards the center of the emerging IS via microtubule 
dynamics [166-169]. However, signaling from those microclusters was already 
reported in the periphery and is rather terminated as soon as the clusters reach the 
cSMAC, especially for strong agonists [167, 170, 171]. The cSMAC is depleted of 
F-actin and therefore enables vesicle formation and release into the synaptic cleft 
[172-175]. It was shown before, that B cells ingest T cell-released vesicles, which 
allowed for continued B cell activation [176]. Besides extracellular vesicle release, 
TCR/pMHC microclusters are also engulfed by the T cells at the cSMAC for 
termination of signaling and recycling of receptors [171, 177-179]. 
 
Fig. 3: Constitution of the T cell IS and integrin activation upon TCR ligation. (A) Schematic 
picture of the top view of a T cell IS depicting the SMACs in concentric rings with major molecules 
located at the respective SMAC written in black. (B) Side view of an IS between T cell (left side) and 
APC (right side) and major contributing molecules from both cell types. Receptors and respective 
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ligands are opposite of each other. (C) Schematic summary of the LFA-1 activation pathway following 
TCR engagement by a pMHC. Detailed information on all figure parts can be found in the text. (A) and 
(B) are adapted from [180], (C) is adapted from [181]. 
 
1.5.2 Integrin activation: inside-out and outside-in 
Integrin activation is crucial for all hematopoietic cells to facilitate cell arrest and 
migration as well as to enable formation of sustained cell-cell interactions as for 
example at the IS [182]. Integrins are heterodimers composed of one out of 18 α 
subunits combined with one out of eight β subunits and they are found in three 
conformations which reflect different activation stages: One bent and two extended 
forms which are of low, intermediate and high affinity towards their ligand, 
respectively. The two extended versions differ in a shift of the headpiece of the β 
subunit exposing the ligand binding pocket and an additional rearrangement of the 
transmembrane and intracellular domains of both subunits [183, 184]. The most 
prominent integrin at the IS is LFA-1, which consists of CD11a (integrin αL) and CD18 
(integrin β2) [184, 185]. During IS formation, LFA-1 is activated downstream TCR 
ligation via inside-out signaling. Briefly, TCR ligation causes the formation of several 
signaling modules, which at least partly affect integrin activation. One example is the 
TCR-triggered recruitment of SLP-76/ADAP/SKAP-55 (SH2 domain-containing 
leukocyte protein of 76 kDa/Adhesion and degranulation promoting adaptor 
protein/Src kinase-associated phosphoprotein of 55 kDa) to the LAT signalosome 
[186-189]. This module serves as docking station for RIAM (Rap1–guanosine 
triphosphate (GTP)-interacting adapter molecule), and RIAM in turn recruits the 
cytoskeletal protein Talin [190-192]. Additionally, Kindlin-3 is recruited to the 
intracellular integrin domains, likely through association with ADAP [193], and also 
binds to the β subunit albeit at a different position than Talin [194]. Another protein 
complex is formed after activation of the small guanosine triphosphatase (GTPase) 
Ras-related protein 1 (Rap1). GTP-bound Rap1 attracts its binding partner RapL 
(Regulator for cell adhesion and polarization enriched in lymphoid tissues) into the 
synapse and RapL directly binds the α subunit of LFA-1 [195, 196]. Additionally, 
active Rap1 also recruits RIAM, again supporting the recruitment of Talin [197, 198]. 
Due to the direct interaction of this adaptor protein with the subunit of LFA-1, 
transition from low affinity to intermediate affinity LFA-1 is mediated. The high affinity 
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state is reached due to the connection of the whole complex on the one side to 
intercellular adhesion molecule-1 (ICAM-1) and on the other side to the actin 
cytoskeleton via Talin, which in sum generates sufficient shear force to completely 
convert LFA-1 to the high affinity conformation (Fig. 3C) [199, 200]. However, high 
affinity conformation of integrins can also be induced by extracellular bivalent cations 
such as Mn2+ via outside-in signaling [201]. Certain tyrosine kinases are associated 
with the intracellular integrin domains and mediate outside-in signaling, thereby, 
submitting information regarding chemical and mechanical properties of the 
environment into the cell [202, 203]. Shutdown of integrin activation is less well 
studied and literature so far suggests that it is probably enabled through another set 
of small GTPases such as Cell division control protein 42 (Cdc42) and Rho-related 
GTP-binding protein H (RhoH) as well as proteases like calpain. Additionally, 
phosphorylation of certain residues within the β subunit of LFA-1 was shown to have 
inhibitory effects [204-208].  
1.6 The small GTPase Rap1 
Rap1 is the major small GTPase implementing integrin activation in T cells with 
regard to LFA-1 activation at the IS [195, 209, 210]. Rap1 is geranylgeranylated and 
therefore constitutively membrane bound [184]. It was reported to be stored in 
intracellular vesicles, which also allow transport of Rap1 to the cell membrane, but 
whether this trafficking is pervasive or a consequence of TCR stimulation remains a 
matter of debate [211, 212]. In the inactive state Rap1 binds guanosine diphosphate 
(GDP) and needs the aid of a guanine nucleotide exchange factor (GEF), which 
triggers release of GDP and thereby enables binding of GTP instead, in order to 
reach the active conformation [213]. Up to date, several Rap1 GEFs have been 
identified: Members of the Epac (Exchange factor directly activated by cAMP), 
PDZ-GEF and CalDAG GEF families, as well as C3G (CRK-SH3 domain binding 
GEF) and Dock4 (Dedicator of cytokinesis protein 4), which belongs to the CDM 
family [214-221]. Hydrolysis of GTP to GDP needs support from a Rap 
GTPase-activating protein (GAP), such as members of the Signal-induced 
proliferation-associated protein 1 (Spa-1) family [222]. As long as both Rap GEFs 
and Rap GAPs are present and activated, Rap1 cycles between the GDP-bound 
inactive and the GTP-bound active state.  
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Rap1 deficiency was shown to result in defective integrin activation affecting cell 
adhesion and migration, thereby impacting lymphocyte homing [223, 224]. 
Additionally, it was shown that integrin activation is indispensable for recognition of 
weak agonists by T cells and therefore Rap1 is involved in the generation of 
appropriate T cell responses [225, 226]. Besides its role in cell adhesion, Rap1 
impacts ERK1/2 activation and ultimately T cell activation, but whether this impact 
activates or rather inhibits ERK1/2 remains controversial. It was reported that Rap1 
reduces ERK1/2 activation, and that this pathway is employed by the costimulatory 
molecule CTLA-4 to mediate T cell inhibition and vice versa CD28 was shown to 
inhibit Rap1, which in turn results in activation of ERK1/2 [226-229]. On the other 
hand, B-Raf was identified as a direct target of Rap1 thereby promoting activation of 
ERK1/2 [230, 231]. Ren et al. had a detailed look at the molecular link between Rap1 
and ERK1/2 and identified that the RapGEF CalDAG GEFI is phosphorylated by 
ERK1/2, which inhibits GEF activity towards Rap1, resulting in a feedback loop 
towards reduced ERK1/2 activation [232]. In summary, it was convincingly shown 
that Rap1 directly interacts with B-Raf and Raf1, which positively or negatively 
regulates ERK1/2, respectively [230, 233]. Therefore, Rap1 might act as both, 
activator and inhibitor of ERK1/2, which might be for instance cell context-dependent 
or an indirect effect of Rap1 [234]. Interestingly, one study also addressed the role of 
Rap1 specifically for Treg development and function. They could show that 
transgenic mice expressing constitutively active Rap1 displayed elevated frequencies 
of CD4+CD103+ Tregs and thus suggest a role for Rap1 in thymic and peripheral 
Treg development, which is at least partly independent of LFA-1 activation. However, 
molecular mechanisms by how Rap1 is affecting Treg development were not clarified 
[235, 236]. 
1.7 The guanine nucleotide exchange factor CalDAG GEFI 
CalDAG GEFI belongs to a family of four GEFs, which were considered to be 
Ca2+ and DAG regulated [195]. CalDAG GEFI (Rasgrp2) expression is mainly 
reported in the nervous and hematopoietic system [237] and CalDAG GEFII 
(Rasgrp1) is the family member majorly abundant in T cells [238]. In B cells, 
preferential CalDAG GEFIII (Rasgrp3) expression was shown [239, 240], and 
Rasgrp4 is expressed specifically in mast cells [241]. CalDAG GEFI was identified 
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and first characterized as a Rap-specific GEF in the brain of rats, highly enriched in 
the striatum and olfactory bulb, and in the hematopoietic system of rat and human 
[216]. It was shown that CalDAG GEFI is massively downregulated in the brain in 
case of Huntington’s disease and it was speculated that this downregulation serves 
as protective mechanism, because knockdown of CalDAG GEFI in an experimental 
model of Huntington’s disease rescued pathology [242]. Regarding the hematopoietic 
system CalDAG GEFI function is best characterized in human and murine platelets 
and neutrophils [237, 243]. Studies regarding T cells are so far solely performed in 
the human system as it was reported that CalDAG GEFI is not expressed by murine 
T cells [184, 237]. All CalDAG GEF family members display an N-terminal Ras 
exchange motif (REM) domain, directly followed by RasGEF (Cdc25-like) domain 
(Fig. 4A). Those two domains commit the guanine nucleotide exchange activity and 
enable the interaction with the respective GTPase. C-terminal of these catalytic 
domains are two EF hand motives, which render the molecule Ca2+ sensitive. At the 
C-terminal part, a C1 domain is located, which is thought to allow binding of phorbol 
esters such as DAG and its synthetic surrogate phorbol 12-myristate 13-acetate 
(PMA) [218]. Although according to literature CalDAG GEFI was considered not to be 
expressed in primary murine T cells [184, 237], our group detected CalDAG GEFI 
present in both ex vivo isolated murine Tregs and Tconv in the course of the 
aforementioned comparative proteome analysis (Fig. 4B) [132]. Besides the mere 
presence, CalDAG GEFI was also found to be phosphorylated at several amino acid 
residues during the performed phosphopeptide sequencing and most strikingly, a 
novel phosphorylation site at Y523 was detected (Fig. 4C) [132]. Additionally, due to 
the comparison of resting and activated Tregs and Tconv, our group identified a 
differential regulation of Y523 in resting Tregs and Tconv, with a reduced 
phosphorylation level in Tregs. Following 5 min stimulation via the TCR, this 
difference was even more pronounced due to the fact that Tconv did not alter the 
phosphorylation level of Y523, while the phosphorylation was massively reduced 
upon stimulation in Tregs (Fig. 4D) [132]. CalDAG GEFI Y523 is located within the 
C1 domain and more precisely in the loop B of the phorbol ester binding pouch 
(Fig. 4E) [244]. C1 domains are well known from protein kinase C family members to 
enable responsiveness towards DAG, and several studies have already addressed 
phorbol ester binding capacities of the CalDAG GEF family members [244-246].  
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Fig. 4: The guanine nucleotide exchange factor CalDAG GEFI. CalDAG GEFI was found to be 
differentially phosphorylated at the so far undescribed site Y523 in primary murine Tregs versus 
Tconv. (A) Schematic overview of the protein domain structure of CalDAG GEFI. The newly identified 
phosphorylation site at Y523 is located within the C-terminal C1 domain (right side) and is highlighted 
in red. Details can be found in the text. (B) Tconv and Tregs were sorted from pooled spleen and LNs 
from BALB/c mice as CD4
+
CD25
-
 and CD4
+
CD25
+
 cells, respectively, for comparative proteomic 
analysis performed recently by our group. Samples were iTRAQ-labeled and analyzed via LC-MS/MS. 
Representative MS spectrum of one of the identifier peptides of CalDAG GEFI is shown with the 
peptide sequence written on the top right. A summary of the iTRAQ ion signal is depicted at the very 
left side of the plot, with Tregs represented by the 115.1 ion displayed in green and Tconv represented 
by the 117.1 ion depicted in yellow. Each peak represents part of the peptide, either starting from the 
N-terminus (bi) or from the C-terminus (yn) of the displayed peptide. (C) Sorted Tconv and Tregs, as 
described above, were either left unstimulated or stimulated via streptavidin-mediated crosslinking of 
biotinylated anti-CD3/28 for 5 min. Cells were lysed and lysates were enriched for phospho-peptides in 
order to perform quantitative phosphoproteomics. Representative MS spectrum of one of the detected 
phospho-peptides of CalDAG GEFI is shown with the peptide sequence written on the top right. A 
summary of the iTRAQ ion signals is depicted at the very left side of the plot, with resting Tregs 
represented by the 115.1 ion displayed in red, resting Tconv represented by the 115.1 ion displayed in 
green, activated Tregs represented by the 116.1 ion displayed in blue and activated Tconv 
represented by the 117.1 ion displayed in yellow. Each peak represents part of the phospho-peptide, 
either starting from the N-terminus (bi) or from the C-terminus (yn) of the detected peptide and the 
phosphorylation of the tyrosine residue becomes apparent from the mass difference of 80 Dalton 
between the peptide y2 in this plot and the peptide y2 from the MS plot displayed in (B), which is 
representing the unphosphorylated state. (D) Excerpt from Figure 2, displaying the phosphorylation 
dynamics at Y523 of CalDAG GEFI in unstimulated (0’) und stimulated (5’), as described above, Tconv 
(two columns on the left) and Tregs (two columns on the right). The respective color code of the 
heatmap is displayed on the left with blue indicating reduced phosphorylation and red displaying 
enhanced phosphorylation. All samples were normalized to the phosphorylation level of unstimulated 
Tconv (left column). (E) Amino acid sequence of the C1 domain of CalDAG GEFI starting from amino 
acid 498 and including the phosphorylated tyrosine residue Y523, highlighted in red. C1 domains were 
shown to bind phorbol esters in a binding pouch and the amino acids contributing to the pouches 
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loops are enframed. (B) and (C) are a kind courtesy of Marco van Ham (HZI, Braunschweig). 
Proteomics and phosphoproteomics were performed by Marco van Ham and colleagues. 
 
So far, it was shown that CalDAG GEFII and CalDAG GEFIII are responsive to 
DAG, while this is not the case for CalDAG GEFI. Regarding Rasgrp4, two splice 
variants exist from which Rasgrp4α binds DAG whereas Rasgrp4β does not. It was 
clearly demonstrated that unresponsiveness of CalDAG GEFI towards DAG and 
analogues thereof is due to amino acid differences within the phorbol ester binding 
pocket of the family members. The residue S506 was proven to be extraordinarily 
important by two independent studies [244, 246], and the latter conducted by Czikora 
and colleagues expanded this to the amino acids N505, A517 and I519. Interestingly, 
although CalDAG GEFI is not binding DAG, it is localized towards the membrane 
following cell stimulation and was also reported to be part of the IS, localizing within 
the pSMAC [247, 248]. Caloca et al. demonstrated that CalDAG GEFI can directly 
interact with F-actin and therefore it is believed that membrane recruitment is 
facilitated via this cytoskeletal interaction [248]. Interestingly, although CalDAG GEFI 
was convincingly shown not to bind DAG or PMA, still a number of studies reported 
PMA-induced CalDAG GEFI activity and subcellular translocation [237, 243, 249, 
250]. CalDAG GEFI is a Rap1-specific GEF and therefore implements integrin 
activation pathways [216]. It was shown before that deficiency in CalDAG GEFI leads 
to impaired cell adhesion and that also cell migration is impaired in absence of 
CalDAG GEFI [237, 243, 249]. CalDAG GEFI-/- mice are healthy and fertile and do 
not show any obvious phenotype [237]. However, closer examination revealed that 
thrombus formation in those mice is impaired due to delayed integrin activation in 
platelets which results in slightly elevated bleeding times following injury [237]. 
CalDAG GEFI-/- neutrophils displayed an aberrant cell adhesion behavior and 
migration towards the site of inflammation was strongly impaired. Therefore, it was 
assumed that defective CalDAG GEFI is the cause for leukocyte adhesion deficiency 
type III (LADIII) and that CalDAG GEFI-/- mice serve as appropriate experimental 
model [243]. However, it was shown in the meantime that LADIII is caused by a 
mutation of Kindlin-3 rather than CalDAG GEFI [251]. Under homeostatic conditions, 
white blood cell count appeared at expected numbers, and as CalDAG GEFI was 
believed to be absent from T cells, no thorough examination of the T cell 
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compartment was performed so far. Published data on CalDAG GEFI’s role in 
various cells of the hematopoietic compartment and especially the reported functional 
impact on human T cells make CalDAG GEFI an interesting target for the T cell field. 
In addition, identification of the differentially regulated novel phosphorylation site in 
Tregs as compared to Tconv allows speculation about T cell subset-specific function 
of CalDAG GEFI. 
1.8 Aims of the study 
It is well established that Tregs maintain immune tolerance by active 
suppression of effector T cell proliferation and that all T cell subsets require 
stimulation via the TCR in order to fulfill their designated effector functions. Moreover, 
there is accumulating evidence that TCR signaling is differentially organized in Tregs 
and Tconv, but the responsible molecular players remain to be elucidated. Using 
comparative proteomics and quantitative phosphopeptide sequencing as well as 
toponome analyzes by MELC, our department identified diverging phosphorylation 
dynamics and recruitment kinetics of phosphorylated components during IS formation 
of Tregs and Tconv [132]. Therefore, we hypothesized that the detected differences 
result in the formation of a Treg-specific IS, and one aim of this study was to gain 
more detailed insight into differentially regulated phosphorylation dynamics following 
TCR ligation in Tregs and Tconv. Besides this general approach to decipher 
Treg-specific IS formation, the role of the candidate molecule CalDAG GEFI was 
analyzed in more detail. The aforementioned phosphoproteomic study identified a 
novel phosphorylation-site of CalDAG GEFI, which we hypothesized to affect IS 
formation and thereby Treg functionality in general. Gathering detailed knowledge on 
Treg-specific characteristics during IS formation might allow for identification of 
targets susceptible to manipulation in order to abrogate or support Treg-IS formation.   
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2. Results 
2.1 Themis expression levels do not affect Treg suppressive capacity in vitro 
Employing proteomic analysis of FACS-sorted ex vivo isolated murine Tconv 
and Tregs, our group could recently identify a number of proteins that are 
differentially expressed in the two examined T cell subsets. Themis is one of the top 
candidates with a significantly reduced expression level in Tregs as compared to 
Tconv [132]. As shown before in other studies, Themis is a component of the TCR 
signalosome and plays an important role during thymocyte positive selection [138, 
252]. Therefore, it was tempting to speculate that overexpression of Themis in 
primary murine Tregs would impair their suppressive capacity. Thus, retroviral 
transduction was employed, which allowed overexpression of murine Themis along 
with Thy1.1, serving as a reporter, in anti-CD3/28 activated CD4+ T cells from 
Foxp3hCD2 reporter mice. Thy1.1+ Tregs were re-sorted and co-cultured with freshly 
FACS-sorted and Cell TraceTM Violet (CTV)-labeled Tnaive at titrated ratios in 
presence of T activator beads. Empty vector transduced Tregs served as control. 
After four days, flow cytometric analysis of the co-culture revealed the dilution of CTV 
in the total Tnaive population quantified by the geometric mean fluorescence intensity 
(Geomean) of CTV (Fig. 5A). Both, Themis-overexpressing and empty 
vector-transduced Tregs were equally able to restrict the proliferation of Tnaive cells 
(Fig. 5B and C). Therefore, in the used experimental setting, elevated Themis 
expression in Tregs has no impact on their suppressive capacity. 
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Fig. 5: In vitro suppression assays using Themis overexpressing Tregs. CD4
+
 T cells were 
MACS-enriched from pooled spleen and LNs of Foxp3
hCD2
 mice and lentivirally transduced with either 
empty vector (MSCV_empty) or vector containing Themis (MSCV_Themis). Transduced Tregs were 
resorted as CD4
+
Foxp3
hCD2+
Thy1.1
+ 
cells and co-cultured with freshly FACS-sorted CTV-labeled 
Tnaive at indicated ratios in presence of T activator beads. On day 4, proliferation-dependent 
CTV-dilution in Tnaive was assessed via flow cytometry. (A) Exemplary gating strategy is depicted: 
First gate was set on lymphocytes and doublets were excluded according to scatter properties of the 
cells. Further gating included living CD4
+
 cells (LD) and separation of Tregs and Tnaive according to 
Foxp3
hCD2
 expression as well as CTV signal. Expression of Thy1.1 as marker for transduced cells was 
verified on Tregs and the Geomean of CTV of the total Tnaive population was determined. Numbers in 
plots represent frequencies in the respective gates. (B) Exemplary histogram plots are shown of 
unstimulated (top left) and bead-stimulated Tnaive (lower left) as controls and Treg:Tnaive co-cultures 
at a ratio of 1:2 (upper panel) and 1:16 (lower panel) using empty vector transduced Tregs 
(MSCV_empty, middle) or Themis overexpressing Tregs (MSCV_Themis, right). Numbers in gates 
represent Geomean of the CTV signal of the Tnaive population. (C) Scatter plot depicts the Geomean 
of CTV of Tnaive cells at indicated Tregs:Tnaive ratios for empty vector (MSCV_empty) and 
Themis-containing vector (MSCV_Themis) transduced Tregs. Mean±SD is depicted from pooled data 
of three independent experiments. 
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2.2 Protein phosphorylation kinetics following TCR ligation in Tregs and 
Tconv 
A phosphoproteome analysis recently performed by our group revealed 
differential phosphorylation dynamics comparing primary murine Tregs and Tconv, 
either in the resting state or after 5 min TCR stimulation (Fig. 2) [132]. Due to high 
requirements of cells and hence mice to purify sufficient numbers of Tregs and Tconv 
for quantitative phosphopeptide sequencing, it was experimentally not feasible to 
generate additional datasets for confirmation of the initial results or for inclusion of 
further stimulation time points. Thus in this study, phosphorylation kinetics in Tregs 
and Tconv following TCR ligation were addressed via flow cytometry using selected 
available antibodies, which allows for analysis at the single cell level and 
performance of kinetics to follow differential phosphorylation events in the two T cell 
subsets over time.  
2.2.1 Phospho-flow cytometry establishment 
To analyze differential phosphorylation in primary murine Tregs and Tconv at 
the single cell level, bulk CD4+ T cells were isolated from pooled spleen and LNs of 
Foxp3hCD2 reporter mice via MACS-enrichment. Cells were stained for CD4 and 
Foxp3hCD2 to enable discrimination of Tregs and Tconv. Subsequently, cells were 
decorated with biotinylated anti-CD3 as well as anti-CD28, pre-warmed at 37 °C and 
stimulated by addition of streptavidin to initiate crosslinking of the biotinylated 
antibodies. In order to determine the optimal stimulation time span a fraction of cells 
was fixed to abrogate all ongoing signaling events over a time course of 30 minutes. 
Subsequently, T cells were permeabilized and intracellular staining for 
phosphorylated ERK1/2 (pERK1/2) was performed. By flow cytometric analysis, 
doublets and dead cells were excluded, and Tregs and Tconv were gated 
subsequently as CD4+Foxp3hCD2+ and CD4+Foxp3hCD2-, respectively (Fig. 6A). The 
isotype control confirmed no unspecific background staining at all analyzed time 
points (Fig. 6A, B and C), and stimulation via PMA/iono served as positive control 
(Fig. 6A). Evaluation of the recorded kinetic revealed the highest frequency of 
pERK1/2+ Tregs and Tconv within the first 5 min of stimulation, followed by a steady 
decrease back to basal phosphorylation levels (Fig. 6B). Obviously, the 
phosphorylation of ERK1/2 is reduced in Tregs as compared to Tconv, which is one 
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of the hallmark differences in TCR signaling of the two T cell subsets (Fig. 6B, C and 
D). Consequently, a second kinetic was performed, focusing on the first 5 min after 
TCR ligation and narrowing the time intervals to 30 sec each. As expected, the 
kinetic confirmed the occurrence of major phosphorylation events within the first 
5 min after TCR triggering with an apex for pERK1/2+ Tregs and Tconv after 3 min of 
antibody crosslinking (Fig. 6C). Subsequently, stimulation conditions were optimized 
in order to retrieve the maximum frequency of pERK1/2+ Tregs and Tconv. Therefore, 
several concentrations were tested ranging from 1/0.5 µg/ml to 80/40 µg/ml of 
anti-CD3/28, respectively. Cells were fixed after 3 min of stimulation and frequency of 
pERK1/2+ cells was analyzed for Tregs and Tconv. The concentrations of 10/5 µg/ml 
anti-CD3/28 resulted in the maximum frequency of pERK1/2+ Tregs and Tconv 
(Fig. 6D) and therefore this stimulation condition was chosen for the following 
phosphorylation kinetics.  
 
Fig. 6: Determination of appropriate time frame and optimal stimulation conditions for 
phospho-flow cytometry. CD4
+
 T cells from pooled spleen and LNs of Foxp3
hCD2
 reporter mice were 
MACS-enriched and stimulated via streptavidin-mediated crosslinking of biotinylated anti-CD3/28. At 
indicated time points, a fraction of the cells was fixed and stained for pERK1/2 or isotype control. (A) 
Exemplary gating strategy depicts gating on living singlet lymphocytes. CD4
+
Foxp3
hCD2+
 Tregs and 
CD4
+
Foxp3
hCD2-
 Tconv were analyzed for pERK1/2
+
 cells following PMA/iono stimulation with gates 
set according to 0 min stimulation control. The isotype control was included in all experiments to 
evaluate unspecific background staining. Numbers indicated in dot plots represent cell frequencies in 
2. Results 
33 
 
the respective gates. (B) Kinetic of the frequency of pERK1/2
+
 Tregs (closed circles) and Tconv 
(closed squares) as well as isotype controls for both T cell subsets (open circles and open squares, 
respectively) over 30 min following addition of streptavidin to induce crosslinking of biotinylated 
stimulation antibodies. (C) Kinetic of the frequency of pERK1/2
+
 Tregs (closed circles) and Tconv 
(closed squares) as well as isotype controls for both T cell subsets (open circles and open squares, 
respectively). (D) Bar graph summarizes the frequencies of pERK1/2
+
 Tregs (closed bars) and Tconv 
(open bars) following 3 min stimulation via crosslinked anti-CD3/28 at indicated concentrations of 
biotinylated stimulation antibodies. Isotype control is not depicted as values were constantly close to 
zero (see (B) and (C)). All experiments were performed once. 
 
2.2.2 Phospho-flow cytometry kinetics for selected molecules 
The major limitation of phospho-flow cytometry is the availability of 
phospho-specific antibodies, which are suitable for flow cytometry. Therefore, 
verification and extension of identified candidates from the phosphoproteomic 
analyses was only possible for CD3ζ pY142, and additionally the present study 
extended to Lck pY505 and ZAP70 pY319, with ERK1/2 pT202/pY204 serving as a 
control [132]. Cells were stimulated and stained as described above and gated 
according to Foxp3hCD2 expression to discriminate Tregs and Tconv. Frequencies of 
pLck+, pCD3ζ+ and pZAP70+ Tregs and Tconv were far below the observed 
frequency for pERK1/2+ cells, which precluded a comparison on the frequency level 
for the two T cell subsets (Fig. 7A). Consequently, the Geomean of the whole Treg 
and Tconv subset for the respective phosphorylation-site was analyzed. In line with 
literature, ERK1/2 phosphorylation is attenuated in Tregs as compared to Tconv, 
palpable from the ascent of the ratio of the Geomean for pERK1/2 (Tconv/Tregs), 
which was not observed for the isotype control (Fig. 7C-E). However, no obvious 
differences in phosphorylation levels and dynamics were detected for Lck pY505, 
CD3ζ pY142 and ZAP70 pY319 in Tregs as compared to Tconv (Fig. 7C-E). For 
CD3ζ pY142 the phosphoproteome detected an elevated phosphorylation state of 
this site in unstimulated Tregs as compared to Tconv, which was not detectable via 
phospho-flow cytometry (Fig. 2 and Fig. 7D), indicating that variations in 
phosphorylation might be beyond the detection limit of phospho-flow cytometry.  
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Fig. 7: Phospho-flow cytometry for pLck pY505, pCD3ζ pY142, pZAP70 pY319 and pERK1/2 
pT202/pY204. CD4
+
 T cells from pooled spleen and LNs of Foxp3
hCD2
 reporter mice were 
MACS-enriched and stimulated via streptavidin-mediated crosslinking of biotinylated anti-CD3/28. At 
indicated time points, a fraction of the cells was fixed and stained intracellularly for the indicated 
phosphorylated protein or isotype control. (A) Exemplary gating strategy on singlet lymphocytes 
depicts: Alive Tregs and Tconv were gated as CD4
+
Foxp3
hCD2+
 and CD4
+
Foxp3
hCD2-
 cells, respectively 
(upper panel), and subsequently the Geomean for the respective phospho-protein for Tregs and 
Tconv was determined as exemplary depicted for pERK1/2 (lower panel, left) and pZAP70 (lower 
panel, right). Numbers in dot plots represent cell frequencies in the respective gates and numbers in 
histogram plots represent the Geomean of the respective population. (B-E) In order to analyze 
diverging phosphorylation kinetics and signal strength, the ratio of the Geomean for Tconv/Tregs was 
determined for each analyzed phospho-protein. An isotype control for the intracellular antibody was 
included in all experiments to evaluate unspecific background staining. Plots depict mean±SD of three 
independent experiments. (B) Kinetic of the Geomean ratio of Tconv/Tregs for pERK1/2 pT202/pY204 
(closed circles) and isotype control (open circles) over 5 min. The increasing ratio indicates reduced 
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Geomean for Tregs as compared to Tconv. (C) Kinetic of the Geomean ratio of Tconv/Tregs for pLck 
pY505 (closed circles) and isotype control (open circles) over 5 min. (D) Kinetic of the Geomean ratio 
of Tconv/Tregs for pCD3ζ pY142 (closed circles) and isotype control (open circles) over 5 min. (E) 
Kinetic of the Geomean ratio of Tconv/Tregs for pZAP70 pY319 (closed circles) and isotype control 
(open circles) over 5 min.  
 
2.3 CalDAG GEFI fine-tunes Treg function 
CalDAG GEFI was detected in murine Tregs and Tconv in both, the proteomic 
study and the phosphopeptide sequencing recently performed in our group (Fig. 2 
and Fig. 4) [132]. The latter study also enabled the identification of a novel 
phosphorylation-site within the C-terminal C1 domain of CalDAG GEFI at Y523. 
Since previous studies did report CalDAG GEFI as being not expressed in murine 
T cells [184, 237], the functional role of CalDAG GEFI in murine T cells has not been 
addressed yet. 
2.3.1 CalDAG GEFI is expressed in primary murine Tregs and Tconv 
To confirm expression of CalDAG GEFI in primary murine Tregs and Tconv, 
both T cell subsets were FACS-sorted as CD4+Foxp3hCD2+ and CD4+Foxp3hCD2-, 
respectively, from pooled spleen and LNs of Foxp3hCD2 reporter mice. Cells were 
lysed and subsequently applied for Western Blot analysis. As expected from the 
proteomic and phosphoproteomic analysis, CalDAG GEFI was clearly detectable in 
both murine T cell subsets with a slightly higher expression level in Tconv as 
compared to Tregs (Fig. 8).  
         
Fig. 8: CalDAG GEFI detection in murine Tregs and Tconv via Western Blotting. Tregs and 
Tconv were FACS-sorted from pooled spleen and LNs from Foxp3
hCD2
 reporter mice as 
CD4
+
Foxp3
hCD2+
 and CD4
+
Foxp3
hCD2-
, respectively. Cells were lysed and equal amounts of protein, as 
determined via BCA assay, were separated by SDS gel electrophoresis. Proteins were blotted on 
PVDF membrane and CalDAG GEFI was detected at the expected molecular weight of 69 kDa via 
anti-Rasgrp2 antibody. Detection of β-actin served as loading control. Data are representative of five 
independent experiments. 
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2.3.2 Phosphorylation at Y523 is not affecting DAG binding of CalDAG GEFI 
The recently identified phosphorylation-site at Y523 of CalDAG GEFI is located 
within the C1 domain of the protein [132], and it is well established that C1 domains 
bind the second messenger lipid DAG as well as other phorbol esters such as the 
DAG analogue PMA [253]. However, it remains controversially discussed whether 
this is also applicable for the C1 domain of CalDAG GEFI [216, 220, 244-246, 248, 
249]. Presence or absence of a negatively charged phosphogroup is influencing the 
local charge of a protein domain and the novel phosphorylation site at Y523 locates 
into the B loop of CalDAG GEFI’s C1 domain (Fig. 4). Therefore, differential 
phosphorylation might result in diverging DAG binding ability of CalDAG GEFI in 
Tregs and Tconv. Thus, the murine C1 domain of CalDAG GEFI was cloned into an 
expression vector and thereby fused to a GST-tag (see section 4.18 for details). In 
collaboration with the group of Prof. Christian Freund from the Free University of 
Berlin, recombinant protein was expressed in E. coli and extracted to high purity. To 
mimic the phosphorylated and dephosphorylated state, Y523 was mutated to Y523D 
and Y523F, respectively. Purified proteins were subjected to membrane lipid PIP strip 
assays and binding to the membrane-spotted lipids was detected via the proteins 
GST-tag. As expected, the GST-tag alone did not show binding to any of the 
provided lipid spots, whereas the manufacturer’s positive control, Pleckstrin 
homology domain of phospholipase δ1 recognizing phosphatidylinositol 
(4,5)-bisphosphate, developed an intense signal. However, none of the tested 
CalDAG GEFI C1 domain versions displayed detectable binding to DAG or any other 
provided lipid (Fig. 9A). To allow for physiological protein folding after recombinant 
expression, the proteins were dialyzed against ZnCl2-containing buffer (Fig. 9B), and 
to rule out adverse effects by glycerol, it was removed from the buffer in an additional 
set of experiments (Fig. 9C). For both preparations of recombinant protein, 
CalDAG GEFI’s C1 domain did not allow for binding to DAG, irrespective of the 
phosphorylation status of Y523. Therefore, differential phosphorylation at Y523 of 
CalDAG GEFI does not lead to diverging DAG-mediated membrane recruitment of 
the protein in Tregs as compared to Tconv, and the functional role of this 
phosphorylation-site remains to be elucidated. 
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Fig. 9: Membrane lipid PIP strips using wild type and Y523D/F phosphomutant CalDAG GEFI. 
The murine CalDAG GEFI C1 domain, either wild type sequence (WT), phosphomimetic version 
(Y523D) and non-phosphorylated version (Y523F), was subcloned into pGEX-4T-1 and thereby fused 
to a GST-tag. Proteins were recombinantly expressed and purified via the GST-tag. Equal amounts of 
protein, as determined by BCA assay, were applied for membrane lipid PIP strips to test lipid binding 
capacity for example to DAG (red frame). Bound proteins were detected via anti-GST antibody. (A) 
Purified proteins were suspended in PBS supplemented with 20 % glycerol and applied to membrane 
lipid PIP strips. The manufacturer’s positive control was included as well as purified GST-tag serving 
as negative control (GST). (B) Recombinant proteins were suspended in PBS supplemented with 
20 % glycerol and 100 µm ZnCl2. Membrane lipid PIP strips for Y523D and Y523F are depicted. (C) 
Recombinant proteins were suspended in PBS 100 µm ZnCl2. Membrane lipid PIP strips for Y523D 
and Y523F are depicted. (A-C) Background staining is in accordance with the method, specific lipid 
binding is detected by a strong signal at the respective lipid spot. Protein expression and purification 
was performed by Eliot Morrison and Annika Manns from the group of Prof. Christian Freund at the 
Free University of Berlin. Results from one out of two to three independent experiments are depicted. 
 
2.3.3 Generation of CalDAG GEFI-/- Jurkat T cell clones and re-expression of 
CalDAG GEFI 
Although the function of the differential phosphorylation of CalDAG GEFI at 
Y523 in Tregs and Tconv remains to be clarified, the general role of this GEF in 
T cells is of interest. CRISPR/Cas9 technology was utilized to generate 
CalDAG GEFI-/- Jurkat T cells in order to address the functional implementation of 
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CalDAG GEFI in T cells. Single guide RNAs (sgRNAs) to target the first exon of 
human CalDAG GEFI were generated employing the online tool http://crispr.mit.edu/ 
(Zhang Lab, MIT, 2015), and oligo nucleotides were cloned into the expression vector 
pX458, which additionally drives transient expression of Cas9 protein and green 
fluorescent protein (GFP) as reporter. Jurkat wild type cells of the clone JE6 were 
transfected and single cells were sorted according to GFP expression 48 h after 
nucleofection into 96-well plates (Fig. 10A). All growing clones were expanded and 
tested for expression of CalDAG GEFI via Western Blot approximately four weeks 
after single cell sorting. Importantly, CalDAG GEFI expression was massively 
reduced in cells from clone 1E8 as compared to wild type cells and was completely 
absent three weeks later. However, 15 weeks after single cell sorting, CalDAG GEFI 
expression recurred, which was either due to inappropriate single cell sorting or 
spontaneous mutation (Fig. 10B, upper panel). Therefore, a second round of single 
cell sorting was applied to “clone” 1E8 and two descendants, referred to as clone #1 
and #2, were expanded and proved to have no detectable expression of 
CalDAG GEFI even 24 weeks after single cell sorting. Sequencing of the genomic 
DNA adjacent to the binding site of the employed sgRNA confirmed a partial deletion 
within exon 1 of CalDAG GEFI for clone #1 and #2. All following experiments 
employing Jurkat T cells were performed with JE6 as wild type control and the two 
CalDAG GEFI-/- clones #1 and #2. 
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Fig. 10: Generation of CalDAG GEFI
-/-
 Jurkat T cell clones by CRISPR/Cas9 technology. Wild 
type Jurkat T cells were transiently electroporated with an expression vector containing a human 
CalDAG GEFI-targeting sgRNA, and coding sequence for Cas9 protein and a GFP reporter. 48 h after 
transfection, single cells were sorted into 96-well round bottom plates. Expression of CalDAG GEFI 
was tested via Western Blotting. (A) Gating strategy for the single cell sorting of transfected Jurkat 
T cells. Cell debris and doublets were excluded according to scatter properties of the cells and GFP
+
 
cells were sorted. Untransfected cells (upper histogram) were used to set the GFP gate. Numbers in 
plots represent cell frequencies in respective gates. (B) Western Blot analysis of the clone 1E8 after 
the first round of single cell sorting (upper panel). First analysis was performed four weeks after single 
cell sorting and repeated seven and 15 weeks after single cell sorting. Second round of single cell 
sorting and analysis of CalDAD GEFI expression via Western Blot for clone #1 and clone #2. 
Expression analyses four weeks and 24 weeks after single cell sorting are depicted (lower panel). Wild 
type (WT) cells served as positive control and β-actin was used as loading control.  
 
As a proof of principle, wild type CalDAG GEFI was re-expressed in both 
CalDAG GEFI-/- Jurkat T cell clones by lentiviral transduction. The employed lentiviral 
vector enabled tracking of transduction efficiency by expression of a GFP reporter. 
Approximately 80 % of the transduced cells were GFP+ 72 h after transduction 
(Fig. 11A), and effective re-expression of the CalDAG GEFI protein was confirmed 
by Western Blot analysis of empty vector control and CalDAG GEFI transduced 
Jurkat T cells as well as untransduced control cells. Expectedly, CalDAG GEFI 
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expression driven by the SFFV promoter provided by the lentiviral expression vector 
was strongly elevated in transduced cells as compared to WT (Fig. 11B). 
 
Fig. 11: Re-expression of CalDAG GEFI in CalDAG GEFI
-/-
 Jurkat T cell clones. CalDAG GEFI 
was re-expressed in CalDAG GEFI
-/-
 Jurkat T cell clones by lentiviral transduction using a vector 
providing a GFP reporter for the determination of transduction efficiency. (A) Exemplary gating 
strategy for the analysis of transduction efficiency via flow cytometry. Cell debris and doublets were 
excluded according to scatter properties of the cells and dead cells were identified by propidium iodide 
(PI) staining (upper panel). GFP
+
 cells were gated according to the signal of GFP
-
 untransduced cells 
(lower panel). (B) Western Blot analysis for CalDAG GEFI expression of untransduced and transduced 
WT Jurkat T cells, as well as clone #1 and #2. Equal amounts of loaded protein were determined by 
β-actin detection. Data are representative of three independent experiments. 
 
2.3.4 CalDAG GEFI-/- Jurkat T cells show deficits in adhesion but retain 
chemotactic behavior 
It was reported before that overexpression of CalDAG GEFI in Jurkat T cells 
results in enhanced adhesion, whereas chemokine-activated Jurkat T cells show 
deficits in adhesion to ICAM-1 following siRNA-mediated silencing of CalDAG GEFI 
expression [249]. Hence, β1 integrin-mediated adhesion to fibronectin and 
β2 integrin-dependent adhesion to ICAM-1 of CalDAG GEFI
-/- Jurkat T cell clones was 
analyzed in collaboration with Dr. Stefanie Kliche from Otto-von-Guericke University 
of Magdeburg. Untransduced WT Jurkat T cells and CalDAG GEFI-/- clones #1 and 
#2 were tested, as well as empty or CalDAG GEFI-containing vector transduced 
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cells. In adhesion assays, cells were kept unstimulated or were treated with MnCl2 to 
induce high-affinity conformation of integrins serving as positive control [201]. 
Expectedly, all tested cells show comparable levels of basic adhesion without any 
stimulation and strong adhesion to fibronectin and ICAM-1 upon MnCl2 treatment 
(Fig. 12A and B, left and second from left). TCR stimulation leads to activation of 
integrins by conformational changes resulting in high ligand affinity, whereas PMA 
induces clustering of integrins with low and intermediate ligand affinity and promotes 
cell adhesion by increased avidity [254]. Subsequent to TCR triggering via anti-CD3, 
both CalDAG GEFI-/- clones displayed significantly reduced adhesion to both 
fibronectin and ICAM-1. Binding was not affected by transduction with empty vector 
control but could be completely rescued by re-expression of CalDAG GEFI (Fig. 12A 
and B, second from right). Therefore, CalDAG GEFI is needed for affinity regulation 
of β1 as well as β2 integrins. Interestingly, also PMA-induced adhesion was affected 
by CalDAG GEFI deficiency, although CalDAG GEFI itself is most likely not 
responsive to PMA, as was shown by the membrane lipid PIP strips. However, after 
PMA treatment both CalDAG GEFI-/- clones displayed significantly reduced adhesion 
to fibronectin as well as to ICAM-1, which was not affected by lentiviral transduction 
with empty vector control (Fig. 12A and B, right). While β1 integrin-dependent 
adhesion to fibronectin could be fully restored by CalDAG GEFI re-expression, this 
was not the case for cell adhesion to ICAM-1. In conclusion, CalDAG GEFI plays a 
role in avidity-induced cell adhesion to β1 integrins, but whether this also applies to 
β2 integrin-dependent cell adhesion remains unclear. In general, CalDAG GEFI is 
required in Jurkat T cells to induced cell adhesion, however, other molecules can 
partly rescue CalDAG GEFI deficiency as CalDAG GEFI-/- clones did not fully 
abrogate adhesion to fibronectin and ICAM-1. 
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Fig. 12: Cell adhesion to fibronectin and ICAM-1 of wild type and CalDAG GEFI
-/-
 Jurkat T cell 
clones. Adhesion properties of wild type Jurkat T cells (WT) and CalDAG GEFI
-/-
 Jurkat T cell clones 
(#1 and #2) to (A) fibronectin or (B) ICAM-1 coated cell culture dishes were tested without stimulation 
(left) and following stimulation via divalent cations (MnCl2, second from left), TCR ligation (αCD3, 
second from right) or phorbol ester treatment (PMA, right). Cells were untransduced, empty vector 
(pRRL_empty) or CalDAG GEFI-containing vector (pRRL_CalDAG GEFI) transduced. Frequency of 
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adherent cells was determined by counting after removal of unbound cells and calculated as % of 
input cells. Mean±SD of three independent experiments is shown. Adhesion experiments were 
performed by Dr. Stefanie Kliche (OvGU, Magdeburg). 
 
Deficiency in CalDAG GEFI was shown to cause reduced migration of 
neutrophils [243]. As adhesion properties of the CalDAG GEFI-/- Jurkat T cell clones 
were impaired, also chemotactic functionality could be altered by CalDAG GEFI 
deficiency. As expected, all examined Jurkat T cells, WT and CalDAG GEFI-/- clones, 
either untransduced or transduced, showed random migration in the absence of a 
chemoattractant (Fig. 13, left part). Upon addition of stroma-cell-derived factor-1 
(SDF-1α), both WT cells and CalDAG GEFI-/- clones migrated towards the 
chemoattractant. In line, transduction and re-expression of CalDAG GEFI had no 
significant influence on chemotaxis of the cells. Although for clone #1, the number of 
migrated cells tended to result in reduced chemotaxis, this slight difference did not 
reach significance and was not affected by CalDAG GEFI re-expression (Fig. 13). 
Thus, in the tested experimental setup, which was done in close cooperation with 
Dr. Stefanie Kliche from Otto-von-Guericke University of Magdeburg, CalDAG GEFI 
deficiency had no impact on migration of Jurkat T cells towards the chemoattractant 
SDF-1α. 
 
Fig. 13: Chemotactic behavior of wild type and CalDAG GEFI
-/-
 Jurkat T cells. Wild type Jurkat 
T cells (WT) and CalDAG GEFI
-/-
 Jurkat T cell clones (#1 and #2), untransduced, empty vector 
(pRRL_empty) or CalDAG GEFI-containing vector (pRRL_CalDAG GEFI) transduced, were tested for 
migration without chemoattractant (medium, left) or towards SDF-1α (right) using fibronectin-coated 
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transwells. The number of migrated cells was determined by counting. Mean±SD of five independent 
experiments is shown. Migration experiments were performed by Dr. Stefanie Kliche (OvGU, 
Magdeburg).  
 
In order to exclude that the reported variations in adhesion of the 
CalDAG GEFI-/- clones were based on altered expression of important surface 
molecules, clones #1 and #2 were characterized for expression levels of CD3, 
CD11a and CXCR4 via flow cytometry. Untransduced WT and CalDAG GEFI-/- clones 
#1 and #2 were tested, as well as empty vector or CalDAG GEFI-containing vector 
transduced cells. In terms of frequencies, no major differences were observed 
regarding the expression of all three examined markers (Fig. 14A and B). Therefore, 
the fold change of the Geomean was assessed to compare expression levels of CD3, 
CD11a and CXCR4. For CD3 and CXCR4 the Geomean confirmed equal expression 
levels on untransduced and transduced cells (Fig. 14C and E). However, CD11a 
expression was significantly reduced on clone #1 and, the phenotype of reduced 
CD11a expression was not influenced by re-expression of CalDAG GEFI, indicating a 
clone-specific feature (Fig. 14D). 
 
Fig. 14: Surface expression of CD3, CD11a and CXCR4 by wild type and CalDAG GEFI
-/-
 Jurkat 
T cells. Surface expression of CD3, CD11a and CXCR4 on wild type Jurkat T cells (WT) as compared 
to CalDAG GEFI
-/-
 Jurkat T cell clones was analyzed via flow cytometry. Empty vector (pRRL_empty), 
CalDAG GEFI-containing vector (pRRL_CalDAG GEFI) or untransduced cells were subjected to 
extracellular staining. (A) Cells were gated as depicted in Fig. 11A and subsequently untransduced 
cells and transduced GFP
+
 were analyzed. Exemplary histogram plots for pRRL_CalDAG GEFI 
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transduced Jurkat T cells of clone #1 are depicted. The Geomean of the signal of the respective 
marker was determined for the whole GFP
-
 (if untransduced) or GFP
+
 (if transduced) cell population. 
Numbers in exemplary histogram plots represent population frequencies of the respective gates. (B) 
Exemplary histogram overlays of the indicated Jurkat T cells for CD3 (left), CD11a (middle) and 
CXCR4 (right). (C-E) Fold change of the Geomean of (C) CD3, (D) CD11a and (E) CXCR4 normalized 
to Geomean of untransduced WT Jurkat T cells is depicted for WT and CalDAG GEFI
-/-
 Jurkat T cell 
clones (#1 and #2), untransduced, empty vector (pRRL_empty) or CalDAG GEFI-containing vector 
(pRRL_CalDAG GEFI) transduced. Mean±SD is depicted and data are pooled from, respectively 
representative of, five independent experiments. 
 
2.3.5 T cell compartment is unaltered in CalDAG GEFI-/- mice 
As CalDAG GEFI expression was not reported in murine T cells until now, the 
T cell compartment of CalDAG GEFI-/- mice was not yet characterized in detail [237]. 
To examine T cell development, thymi from CalDAG GEFI+/+, CalDAG GEFI+/- and 
CalDAG GEFI-/- mice were isolated and single cell suspensions were analyzed by 
flow cytometry. Alive, single lymphocytes were gated and frequencies of 
CD4-CD8- double negative (DN), CD4+CD8+ double positive (DP) as well as 
CD4+ and CD8+ single positive (CD4SP and CD8SP, respectively) cell populations 
appeared unaltered in CalDAG GEFI+/+, CalDAG GEFI+/- and CalDAG GEFI-/- mice, 
and this also applied for Foxp3- and Foxp3+ cells among CD4SP thymocytes 
(Fig. 15A and B). Similarly, Treg precursors defined as CD4+CD25+Foxp3- or 
CD4+CD25-Foxp3+ as well as CD4+CD25+Foxp3+ Tregs and 
CD4+CD25-Foxp3- Tconv were found at expected frequencies (Fig. 15A and C). 
Maturation of Foxp3- and Foxp3+ CD4SP thymocytes was assessed through 
expression of the surface marker CD24, and no differences in maturation of the 
examined T cells subsets depending on CalDAG GEFI expression were observed 
(Fig. 15A and D). Furthermore, absolute numbers of different thymic T cells 
populations were unaffected by CalDAG GEFI deficiency (Suppl. Fig. 1), indicating 
that CalDAG GEFI is not affecting thymic T cell development. 
2. Results 
46 
 
 
Fig. 15: Flow cytometric analysis of the thymic T cell compartment from CalDAG GEFI
+/+
, 
CalDAG GEFI
+/-
and CalDAG GEFI
-/-
 mice. Single cell suspension from thymi from CalDAG GEFI
+/+ 
(WT) CalDAG GEFI
+/- 
(HET) and CalDAG GEFI
-/-
 (KO) mice were analyzed for the indicated markers. 
(A) Exemplary gating strategy is depicted. Alive, single lymphocytes were gated on CD4
-
CD8
-
 (DN), 
CD4
+
CD8
+
 (DP), CD4
+
CD8
-
 (CD4SP) and CD4
-
CD8
+
 (CD8SP). Amongst CD4SP it was further gated 
on CD25
-
Foxp3
-
, CD25
-
Foxp3
+
, CD25
+
Foxp3
-
 and CD25
+
Foxp3
+
 cells. Furthermore, CD24
high
, CD24
int
 
and CD24
low
 subsets amongst CD4
+
Foxp3
-
 and CD4
+
Foxp3
+
 cells were gated. Numbers in dot plots 
represent cell frequencies in respective gates. (B-D) Scatter plots summarize frequencies of the 
indicated cell population from WT, HET and KO mice: For (B) general T cell development including 
CD4 and CD8 (upper panel) and Foxp3
-
 and Foxp3
+
 amongst CD4SP thymocytes (lower panel), (C) 
CD25
-
Foxp3
-
 Tconv, two Treg precursor subsets (CD25
+
Foxp3
-
 and CD25
-
Foxp3
+
) and double 
positive Tregs (CD25
+
Foxp3
+
), as well as (D) maturation stages according to CD24 expression 
(CD24
high
, CD24
int
 and CD24
low
) amongst Foxp3
- 
(upper panel) and Foxp3
+
 CD4SP thymocytes (lower 
panel). Mean of each group is depicted and each data point in scatter plots represents an individual 
mouse (n=11-22 per group). Data are pooled from ten independently performed experiments. 
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Peripheral T cell homeostasis was assessed in single cell suspensions from 
pooled spleen and LNs. No alterations between CalDAG GEFI+/+, 
CalDAG GEFI+/- and CalDAG GEFI-/- mice regarding population frequency and 
absolute numbers of total CD3+ as well as CD4+ and CD8+ subsets amongst CD3+ 
cells were detected. In line with these findings, amongst CD3+CD4+ cells, CD62Lhigh 
Tnaive, Foxp3- Tconv and Foxp3+ Tregs, as well as Nrp1+ cells amongst Tregs were 
observed at equal frequencies and absolute numbers in all genotypes tested 
(Fig. 16A, B and Suppl. Fig. 2). As expected for homeostatic conditions, CD25 was 
nearly exclusively detectable on CD3+CD4+Foxp3+ cells (Fig. 16A). In conclusion, 
CalDAG GEFI-/- mice do not show any aberrations within the T cell compartment in 
SLOs under steady state conditions.  
 
Fig. 16: Flow cytometric analysis of the T cell compartment from SLOs from CalDAG GEFI
+/+
, 
CalDAG GEFI
+/-
and CalDAG GEFI
-/-
 mice. Single cell suspension from pooled spleen and LNs from 
CalDAG GEFI
+/+ 
(WT) CalDAG GEFI
+/- 
(HET) and CalDAG GEFI
-/-
 (KO) mice were analyzed. (A) 
Exemplary gating strategy is depicted. Alive, single lymphocytes were gated on CD3
+
 and CD4
+
 cells 
and subsequently on CD62L
+
 as well as Foxp3
-
 Tconv and Foxp3
+
 Tregs amongst CD3
+
CD4
+
, and 
Nrp1
+
 cells amongst Tregs. Numbers in dot plots represent cell frequencies in respective gates. (B) 
Summarizing scatter plots of frequencies of the indicated cell population from WT, HET and KO mice. 
Mean of each group is depicted and each data point in scatter plots represents an individual mouse 
(n=11-24 per group). Data are pooled from ten independently performed experiments. 
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2.3.6 Signal transduction remains unaltered in CalDAG GEFI-/- T cells 
Previous studies reported that over-expression of CalDAG GEFI in 
HEK293T cells results in reduced activation of Elk1 [216]. Thus, ERK1/2 
phosphorylation might be altered in T cells from CalDAG GEFI-/- mice. To test this 
hypothesis, lymphocytes from pooled spleen and LNs from CalDAG GEFI+/+ and 
CalDAG GEFI-/- mice were stained for CD4 and CD25 and stimulated via 
streptavidin-mediated crosslinking of biotinylated anti-CD3/28 as described above, to 
determine phosphorylation of ERK1/2 over time. First, expression levels of total 
ERK1/2 in Tconv and Tregs from CalDAG GEFI+/+, CalDAG GEFI+/- and 
CalDAG GEFI-/- mice were determined via intracellular flow cytometry. As depicted in 
Figure 17A, 100 % of Tconv and Tregs were ERK1/2+ and also in terms of Geomean, 
no variations were detectable. For pERK1/2 kinetics, pERK1/2+ cells were set 
according to the basal pERK1/2+ frequency at 0 min of stimulation before addition of 
streptavidin for Foxp3- Tconv and Foxp3+ Tregs. Staining with the appropriate isotype 
control did not result in detectable background signals at any analyzed time point 
(Fig. 17B). Consistent with literature, generally lower frequencies of pERK1/2+ Tregs 
were observed as compared to Tconv (Fig. 17C) [156]. In contrast to the 
aforementioned hypothesis, no differences were observed regarding pERK1/2+ Tregs 
or Tconv from CalDAG GEFI+/+ versus CalDAG GEFI-/- mice. Although for Tconv a 
trend for elevated frequencies of pERK1/2+ cells from CalDAG GEFI+/+ mice was 
detected, this difference did not reach statistical significance and additionally was not 
applicable for Tregs (Fig. 17C). In conclusion, ERK1/2 activation in primary murine 
T cells is not affected by CalDAG GEFI deficiency.  
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Fig. 17: Phospho-flow cytometry for pERK1/2 pT202/pY204 in Tregs and Tconv from 
CalDAG GEFI
+/+ 
and CalDAG GEFI
-/-
 mice. Single cell suspensions from pooled spleen and LNs from 
CalDAG GEFI
+/+ 
(WT) and CalDAG GEFI
-/-
 (KO) mice were stained for CD4 and stimulated via 
streptavidin-mediated crosslinking of biotinylated anti-CD3/28 antibodies. Cells were fixed at indicated 
time points and intracellularly stained for total ERK1/2, pERK1/2 pT202/pY204 and Foxp3. (A) 
Exemplary gating strategy depicts alive, single CD4
+
 lymphocytes of a WT mouse gated Tconv and 
Tregs according to Foxp3 expression (middle panel and lower panel, respectively). Gates for 
determination of pERK1/2
+ 
cells were set according to 0 min stimulation control (middle and lower 
panel, left) and exemplary histogram plots depict 1.75 min of anti-CD3/28 crosslinking for pERK1/2 
(middle and lower panel, center) and isotype control (middle and lower panel, right). (B) Gating was 
performed as described in (A) to determine total ERK1/2 expression in WT (blue) and KO (red) Tconv 
(upper panel) and Tregs (lower panel) with FMO (black) serving as staining control. (C) Summarizing 
kinetic of ERK1/2 phosphorylation in Tconv (upper panel) and Tregs (lower panel) from WT (closed 
circles) and KO (open circles) mice. Data are pooled from, respectively representative of, five 
independent experiments, mean±SD is depicted (n=10 mice per group). 
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In order to assess phosphorylation-dependent signal transduction processes 
globally, CD4+ T cells from pooled spleen and LNs from CalDAG GEFI+/+, 
CalDAG GEFI+/- and CalDAG GEFI-/- mice were MACS-enriched, stimulated and 
applied for total phosphotyrosine Western Blot analysis. As controls, cells were either 
kept on ice or incubated in medium at 37 °C for 5 minutes, whereas stimulation was 
carried out via streptavidin-mediated crosslinking of biotinylated anti-CD3/28, 
PMA/iono or pervanadate treatment for 5 minutes. As expected, nearly no 
phosphotyrosines were detectable from freshly ex vivo isolated CD4+ T cells in both 
stimulation controls, whereas all applied stimulation conditions resulted in 
phosphorylation of tyrosine residues corresponding to the applied stimulus strength. 
However, no major differences were observed for CD4+ T cells from CalDAG GEFI+/+, 
CalDAG GEFI+/- and CalDAG GEFI-/- mice (Fig. 18). In summary, global 
phosphorylation-dependent signal transduction processes and particularly ERK1/2 
phosphorylation are not affected by loss of CalDAG GEFI in primary murine CD4+ 
T cells. 
 
Fig. 18: Phospho-tyrosine analysis of CD4
+
 T cells from CalDAG GEFI
+/+
, CalDAG GEFI
+/- 
and 
CalDAG GEFI
-/-
 mice. CD4
+
 T cells from pooled spleen and LNs from CalDAG GEFI
+/+ 
(WT), 
CalDAG GEFI
+/- 
(HET) and CalDAG GEFI
-/-
 (KO) mice were MACS-enriched and were either kept 
unstimulated on ice (left) or were incubated for 5 min at 37 °C (second from left) in cRPMI as negative 
controls. For stimulation, part of the cells were treated with sodium pervanadate (Na3VO4, middle), 
stimulated via streptavidin-mediated crosslinking of anti-CD3/28 (αCD3/28, second from right) or 
treated with PMA/iono (right) for 5 min at 37 °C. Subsequently, cell were lysed and total tyrosine 
phosphorylation (pY) was assessed via Western Blotting, with β-actin serving as loading control and 
detection of CalDAG GEFI as genotype control of the employed mice. Data depicted are 
representative of three independent experiments. 
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2.3.7 CalDAG GEFI-/- Tregs are fully functional in vitro 
As CalDAG GEFI is differentially phosphorylated in Tregs versus Tconv, 
functional properties of CalDAG GEFI-/- Tregs were examined. Ex vivo isolated 
lymphocytes from pooled spleen and LNs of CalDAG GEFI+/+, CalDAG GEFI+/- and 
CalDAG GEFI-/- mice were MACS-enriched for CD4+ T cells, FACS-sorted as 
CD4+CD25+ Tregs and pre-activated for 72 h on plate bound anti-CD3/28 antibodies 
in presence of IL-2. FACS-sorted and CTV-labeled CD4+CD25-CD62Lhigh Tnaive 
were co-cultured at different ratios with pre-activated CD4+CD25+ Tregs with 
T activator beads as stimulus. After four days, cells were analyzed by flow cytometry. 
First, the in vitro suppressive capacity of CalDAG GEFI+/+, CalDAG GEFI+/- and 
CalDAG GEFI-/- Tregs was determined by quantification of the Geomean of CTV of 
the total Tnaive population (Fig. 19A). Expectedly, Tnaive in absence of Tregs and 
T activator beads did not proliferate and sustained a high CTV signal, whereas 
Tnaive stimulated with T activator beads in the absence of Tregs divided and gave 
rise to up to five cell divisions. However, Tregs from CalDAG GEFI+/+, 
CalDAG GEFI+/- and CalDAG GEFI-/- mice were equally able to suppress the 
proliferation of Tnaive corresponding to the ratio of co-cultured Tnaive:Tregs 
(Fig. 19B and C). Second, the stability of Tregs was analyzed by intracellular Foxp3 
staining, and frequencies of Foxp3+ cells amongst CD4+CTV- cells were determined 
(Fig. 19A and D). Around 65 % of co-cultured Tregs from CalDAG GEFI+/+, 
CalDAG GEFI+/- and CalDAG GEFI-/- mice retained stable Foxp3 expression 
(Fig. 19D). In summary, these findings show that CalDAG GEFI expression is 
dispensable for suppressive capacity of Tregs in vitro and it is not critical for the 
maintenance of Foxp3 expression. 
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Fig. 19: In vitro suppression assay using Tregs from CalDAG GEFI
+/+
, CalDAG GEFI
+/- 
and 
CalDAG GEFI
-/-
 mice. Tregs from CalDAG GEFI
+/+ 
(WT) CalDAG GEFI
+/- 
(HET) and 
CalDAG GEFI
-/-
 (KO) mice were FACS-sorted from pooled spleen and LNs as CD4
+
CD25
+
 cells and 
pre-activated for 72 h on plate-bound anti-CD3/28. Freshly sorted and CTV-labeled Tnaive were 
co-cultured with pre-activated Tregs at indicated ratios and on day 4 proliferation-dependent 
CTV-dilution was analyzed via flow cytometry. (A) Exemplary gating strategy is depicted based on 
pregated lymphocyte singlets: Alive CD4
+
 T cells were gated as CTV
- 
Tregs and CTV
+
 Tnaive, to 
assess stability of Foxp3 expression in Tregs and to determine the Geomean of CTV of the total 
Tnaive population. (B) Exemplary histogram plots gated on Tnaive cells after four days co-culture with 
WT (top), HET (middle) and KO (bottom) Tregs at indicated ratios. Unstimulated Tnaive and Tnaive 
without addition of Tregs (0:1) served as controls. Numbers in gates represent Geomean of CTV of 
Tnaive. (C) Plot summarizes the Geomean of the CTV signal of Tnaive cells with or without 
co-cultured Tregs from WT (closed black circles), HET (closed gray circle) or KO (open circles) mice at 
indicated ratios. (D) Scatter plot summarizes the stability of Foxp3 expression within gated Tregs from 
WT (closed black circles), HET (closed gray circle) or KO (open circles) mice after four days co-culture 
with Tnaive at indicated ratios. Data are representative of three independent experiments and 
mean±SD is depicted. 
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2.3.8 CalDAG GEFI fine-tunes Treg suppressive ability in vivo 
CalDAG GEFI-/- Tregs did not show any defect in the suppression of Tnaive 
proliferation in vitro under T activator bead stimulation. To address Treg suppressive 
capacity under more physiological conditions, CalDAG GEFI-/- Tregs were tested in 
an in vivo model of transfer colitis. Tregs were FACS-sorted as CD4+CD25+ cells 
from pooled spleen and LNs from CalDAG GEFI+/+ and CalDAG GEFI-/- mice, and 
co-transferred with CD4+CD25-CD62Lhigh Tnaive from CalDAG GEFI+/+ mice at a ratio 
of 1:4 into Rag2-/- recipient mice via intraperitoneal injection. PBS-treated mice or 
mice receiving only Tnaive without Tregs served as controls. Body weight and 
general health status of recipient mice was monitored biweekly over ten weeks. Mice 
that lost >20 % of initial body weight were sacrificed. As expected, PBS recipients 
gained weight continuously, whereas Tnaive recipients started to lose body weight 
rapidly upon seven weeks after adoptive transfer. Mice receiving Tnaive together with 
Tregs also moderately lost weight from seven weeks onward, but did not show 
significant differences with respect to the source of Tregs (Fig. 20A). Endpoint 
analyses of the experiment included a histological examination and measurement of 
colon length, weight and cellularity of spleen as well as flow cytometric analyses of 
the T cell compartment of spleen, mesenteric and peripheral LN (mLN and pLN, 
respectively). No variations between the two treatment groups were detected 
regarding colon length, spleen weight and organ cellularity (Fig. 20B, C and D). 
Histological scores of Tnaive recipients were drastically elevated in comparison to 
PBS recipients, whereas Tnaive plus Treg recipient scores were intermediate to the 
two control groups indicating a partial suppression of colitis development under these 
conditions. A direct comparison of CalDAG GEFI+/+ or CalDAG GEFI-/- Treg recipients 
did not show statistically significant differences. However, the histological score of 
CalDAG GEFI-/- Treg recipient mice was virtually identical to that of Tnaive recipients 
without addition of Tregs, whereas the score of CalDAG GEFI+/+ Treg recipients 
scattered enormously and was also not significantly different from the score of the 
negative control (Fig. 20E). Expectedly, exemplary photographs from H&E stained 
colon sections showed strong hyperplasia of the epithelium of all T cell recipients and 
transmural immigration of inflammatory cells, mainly lymphocytes (Fig. 20F). 
2. Results 
54 
 
 
Fig. 20: In vivo suppression assay employing the transfer colitis model using Tregs:Tnaive at a 
ratio of 1:4. Tregs from pooled spleen and LNs from CalDAG GEFI
+/+ 
(WT) and CalDAG GEFI
-/-
 (KO) 
mice were FACS-sorted as CD4
+
CD25
+
 cells and co-transferred with CD4
+
CD25
-
CD62L
high
 Tnaive 
from CalDAG GEFI
+/+
 mice at a ratio of 1:4 into Rag2
-/-
 recipient mice via intraperitoneal injection. (A) 
Body weight of mice, which received PBS (grey), only Tnaive cells (black), Tnaive plus WT Tregs 
(blue) or Tnaive plus KO Tregs (red), was monitored biweekly up to ten weeks. Mean±SD is depicted. 
(B) Colon length was measured as inflammation readout as well as (C) weight and (D) cellularity of the 
spleen at the termination of the experiment. (E) Colons were analyzed via histology and scored 
according to severity of inflammation by Dr. Marina Pils (Mousepathology, HZI, Braunschweig). 
Scatter plot depicts the total histology scores with a maximum value of 16. (F) Exemplary photographs 
from H&E stained colon sections from PBS (left), Tnaive (second from left), Tnaive plus WT Tregs 
(second from right) or Tnaive plus KO Tregs (right) receiving mice at a magnification of 10x (upper 
panel) and 20x (lower panel). Scale bars represent 100 µm and 50 µm for the 10x and 20x 
magnification, respectively. Data are pooled from two independent experiments, scatter plots depict 
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mean of each group and each data point in scatter plots represents a single recipient mouse (n=6-10 
mice per group). 
 
Single cell suspensions from spleen, mLN and pLN were analyzed for 
frequencies and absolute numbers of CD3+ and CD3+CD4+, CD44+CD62L- memory 
T cells, Foxp3- Tconv, Foxp3+ Tregs as well as Foxp3+CTLA-4+ and Foxp3+CD103+ 
amongst CD3+CD4+, and CTLA-4+CD103+ double positive amongst Tregs (Fig. 21A). 
All examined populations appeared at comparable frequencies and absolute 
numbers in mice which received Tnaive in combination with either CalDAG GEFI+/+ or 
CalDAG GEFI-/- Tregs (Fig. 21B and Suppl. Fig. 3).  
 
Fig. 21: Flow cytometric analysis of the splenic T cell compartment from transfer colitis 
experiments with Tregs:Tnaive at a ratio of 1:4. Analysis of the transfer colitis experiments included 
flow cytometry for the injected T cells from SLOs of Rag2
-/-
 recipient mice transferred with Tnaive plus 
CalDAG GEFI
+/+ 
or plus CalDAG GEFI
-/-
 Tregs. (A) Exemplary gating strategy for single cell 
suspensions from spleen. It was gated on living singlet lymphocytes and subsequently on CD3
+
 and 
CD4
+
 cells, which were analyzed for expression of Foxp3, CTLA-4, CD25 and CD103. (B) Scatter 
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plots summarize respective population frequencies of splenocytes from recipient mice transferred with 
Tnaive plus CalDAG GEFI
+/+
 (WT) or plus CalDAG GEFI
-/-
 (KO) Tregs. Data are representative of two 
independent experiments, mean of each group is depicted and each data point in scatter plots 
represents an individual mouse (n=10 mice per group). 
 
To assess the impact of a higher proportion of Tregs on the development of 
colon inflammation, the ratio of injected Tnaive:Tregs was adjusted to 1:2 for the 
following experiments. Measurement of body weight revealed no significant 
differences between the two Treg-receiving groups (Fig. 22A). For colon length, only 
a minor but expected reduction was detected for the Tnaive-receiving positive control 
while all other groups did not show differences (Fig. 22B). This was in line with 
spleen cellularity and weight (Fig. 22C and D). Injection of an increased number of 
Tregs resulted in a drop of the histology score of the CalDAG GEFI-/- Treg-receiving 
group, which now appeared largely identical to the CalDAG GEFI+/+ Treg recipients, 
although still with considerable variance within the two Treg-receiving groups 
(Fig. 22E). 
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Fig. 22: In vivo suppression assay employing the transfer colitis model using Tregs:Tnaive at a 
ratio of 1:2. FACS-sorted CD4
+
CD25
+ 
Tregs from pooled spleen and LNs from CalDAG GEFI
+/+ 
(WT) 
and CalDAG GEFI
-/-
 (KO) mice were co-transferred with Tnaive, FACS-sorted as CD4
+
CD25
-
CD62L
high
 
from CalDAG GEFI
+/+
 mice, at a ratio of 1:2 into Rag2
-/-
 recipient mice via intraperitoneal injection. (A) 
Body weight of recipient mice, which received PBS (grey) as negative control, Tnaive cells (black) as 
positive control, Tnaive plus WT Tregs (blue) or Tnaive plus KO Tregs (red), was monitored biweekly 
over a maximum of ten weeks. Mean±SD is depicted. As inflammation readout at the termination of 
the experiment, (B) colon length was measured as well as (C) weight and (D) total cellularity of the 
spleen. (E) Histology scores according to severity of inflammation of colons were determined by Dr. 
Marina Pils (Mousepathology, HZI, Braunschweig). Scatter plot depicts the total histology scores with 
a maximum value of 16. Data are pooled from two independent experiments and each data point in 
scatter plots represents an individual recipient mouse (n=9-12 mice per group).  
 
In line with histology scores, no differences were observed by flow cytometric 
analyses of the T cell compartment of spleen, mLN and pLN for the populations 
mentioned above (Fig. 23 and data not shown). 
 
Fig. 23: Flow cytometric analysis of the splenic T cell compartment from transfer colitis 
experiments with Tregs:Tnaive at a ratio of 1:2. Injected T cells from spleen of Rag2
-/-
 recipient 
mice transferred with Tnaive plus CalDAG GEFI
+/+ 
or plus CalDAG GEFI
-/-
 Tregs were analyzed by 
flow cytometry for frequencies of CD3
+
 and CD4
+
 cells, and subsequently for expression of Foxp3, 
CTLA-4, CD25 and CD103. Gating was performed as shown in Fig. 21A. Scatter plots summarize 
respective population frequencies of splenocytes from recipient mice transferred with Tnaive plus 
CalDAG GEFI
+/+
 (WT) or plus CalDAG GEFI
-/-
 (KO) Tregs. Mean is depicted for each group and each 
dot in scatter plots represents an individual mouse (n=9-10 mice per group). Data are pooled from two 
independently performed experiments. 
 
Additionally, small intestine lamina propria lymphocytes were isolated and 
analyzed via flow cytometry as introduced above. Regarding frequencies, again no 
significant differences were observed, although there were slight trends for elevated 
frequencies of CD4+ T cells , memory T cells and all assessed Treg subsets for 
2. Results 
58 
 
CalDAG GEFI-/- Treg recipients as compared to CalDAG GEFI+/+ Treg recipients 
(Fig. 24A). In line with these findings, absolute numbers of all analyzed T cell 
populations were significantly increased in the CalDAG GEFI-/- Treg-receiving group 
(Fig. 24B). In summary, CalDAG GEFI has a minor impact on Treg suppressive 
capacity in vivo, though this effect is only apparent at certain Tnaive:Treg ratios and 
can be overcome by sufficient Treg numbers. 
 
Fig. 24: Flow cytometric analysis of the T cell compartment of small intestinal lamina propria 
lymphocytes from transfer colitis experiments with Tregs:Tnaive at a ratio of 1:2. Lymphocytes 
were isolated from the small intestinal lamina propria of Rag2
-/-
 recipient mice transferred with Tnaive 
plus CalDAG GEFI
+/+
 or plus CalDAG GEFI
-/-
 Tregs and analyzed via flow cytometry. Gating was 
performed as shown in Fig. 21A. (A) Scatter plots summarize indicated population frequencies of 
siLPLs from recipient mice transferred with Tnaive plus CalDAG GEFI
+/+
 (WT) or plus 
CalDAG GEFI
-/-
 (KO) Tregs. (B) Total cell count of isolated siLPLs was determined by using Accuri 
flow cytometer and absolute numbers of the indicated cell populations were calculated respective to 
their measured frequency. Mean of each group is depicted and each dot in scatter plots represents an 
individual mouse (n=9-10 mice per group). Data are pooled from two independent experiments. 
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3. Discussion 
Tregs are in the spotlight of immunological research since nearly three decades 
and decent amount of data were collected regarding unique features and 
mechanisms of action of Tregs. Regarding health and disease, Tregs represent a 
double-edged sword as on the one side appropriate Treg function is needed to 
maintain self-tolerance and avoid e.g. autoimmunity and allergy, whereas on the 
other hand Tregs can have detrimental impact in the context of cancer or chronic 
infection [50-54]. Therefore, there is an urgent need to pinpoint unique proteins, 
signaling pathways and modes of action of Tregs to gather better understanding of 
this T cell subset and potentially find new targets that allow therapeutic manipulation 
in the one or the other direction. Only in recent years, it became evident that the 
protein inventory of Tregs and Tconv is predominantly comparable, and therefore, 
interest is switching towards identification of signaling processes which are uniquely 
used by Tregs and might allow for functional interference [129, 131, 132, 158-161]. 
“Big data” analyses from comparative screens of e.g. posttranslational modifications 
have permitted an educated guess for possible targets. Still it remains very 
demanding to unravel signaling peculiarities, especially because signal transduction 
pathways are usually not straight-lined but interconnected and interdependent, and 
current cutting edge techniques do not allow revealing these interconnections easily. 
However, as a fact, TCR signaling is an indispensable prerequisite for T cell function 
and the IS is a primary hub of TCR signal initiation. There is accumulating evidence 
that TCR signaling differs in Tregs and Tconv and therefore, the IS and TCR 
signaling serve a promising starting point to further unravel specialties of Tregs as 
compared to Tconv. In this study, the role of Themis and CalDAG GEFI on Treg 
function was examined, as both proteins represent promising candidates that might 
contribute to Treg-specific IS formation. Additionally, phosphorylation-specific flow 
cytometry as state of the art technique was employed to expand knowledge on 
signaling differences between Tregs and Tconv circumventing material intense 
screening methods. 
3.1  The role of Themis in Treg development and function 
Themis is one of the proteins which is differentially expressed in Tregs as 
compared to Tconv, and so far the functional role of this difference was not 
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unraveled. Several studies find Themis underrepresented in Tregs as compared to 
Tconv, both on mRNA and protein level [118, 132, 139]. Themis is recruited to the 
LAT signalosome following TCR ligation via direct interaction with GRB2 and SHP-1 
[136, 137, 252]. Earlier publications reported that Themis acts as a TCR inhibitor, 
which adjusts the tight signal threshold at the transition of positive to negative 
selection in the thymus. Accordingly, Themis knockdown in Jurkat T cells or human 
CD4+ T cells from blood results in elevated ERK1/2 phosphorylation and upregulation 
of activation markers such as CD25 and CD69 [137, 140, 255]. Only recently, it was 
identified that due to direct interaction with SHP-1, Themis actually dampens SHP-1 
phosphatase activity and thereby ultimately enhances TCR signaling [138]. A 
possible explanation for these contradictory results is given by Choi and colleagues: 
It is reported that Themis affects phosphatase activity of SHP-1, but it is not known 
whether also Tyrosine-protein phosphatase non-receptor type 11 (PTPN11, SHP-2) 
is a target of Themis. SHP-2 is a known enhancer of ERK1/2 phosphorylation [256, 
257], and if its activity is independent of Themis, it could be responsible for elevated 
T cell activation in absence of Themis [138]. Though, it is also conceivable that 
Themis functions contrarily during T cell development in the thymus and T cell 
activation in SLOs. In line with its crucial role during thymocyte maturation, Themis 
expression levels are elevated in thymocytes as compared to T cells from SLOs 
[258]. Apart from T cell development, differential expression levels of Themis in 
peripheral Tregs and Tconv as well as published divergent ERK1/2 activation levels 
in the two T cell subsets support the postulated signal-enhancing role for Themis: 
Themis expression is reduced specifically in Tregs as compared to Tconv, and also 
ERK1/2 activation and Ca2+ flux are attenuated in this T cell subset [118, 139, 155-
157].  
Hence, it was tempting to speculate that Themis impacts suppressive activity of 
Tregs. In the present study, Tregs were transduced in order to overexpress Themis 
and the suppressive capacity of these Tregs was assessed in in vitro suppression 
assays. Themis-overexpressing Tregs were found to be as suppressive as 
control-transduced Tregs. In conclusion, the reduced expression level of Themis 
specifically in Tregs has no impact on their suppressive function in the tested 
experimental setup. Though, these results are opposing to a recent report, which 
states elevated suppressive capacity of Themis-overexpressing Tregs both in vitro 
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and in vivo [139]. Duguet et al. isolated Tregs from transgenic mice expressing 
Themis under the control of the human CD2 promoter, which results in raised Themis 
expression in all T cells, including Tregs, in vivo [139, 259]. In vitro, 
Themis-transgenic (Themis-tg) Tregs showed a survival benefit over WT Tregs, 
which is not due to advanced proliferation. This corresponds to another report, which 
also identifies a survival-promoting role for Themis [137]. Interestingly, thymic T cell 
development is unaffected in Themis-tg mice, which might be due to the fact that 
Themis expression levels are upregulated during thymocyte development [259]. The 
finding that Themis-tg Tregs are more suppressive correlates with the hypothesis of 
Choi et al. of Themis as signaling enhancer. The discrepancy regarding suppressive 
capacity of retrovirally transduced Tregs and Themis-tg Tregs might result from the 
respective experimental setting. In order to transduce ex vivo isolated T cells, 
pre-activation was necessary, which might cover slight functional differences 
between control Tregs and Themis-overexpressing Tregs.  
In conclusion, although Themis expression levels might have a minor impact on 
Treg suppressive capacity, this protein appears rather unsuitable for Treg-specific 
manipulation, but might be an interesting target in effector T cells. A blockade of 
Themis function would rather affect Tconv, due to reduced Themis levels in Tregs, 
and results in enhanced T cell activation [137, 140, 255]. As Themis expression 
levels are only mildly affecting Treg function, it would be interesting to investigate 
elevated Themis levels in effector T cells, which according to Choi et al. should result 
in augmented T cell activation [138] and might prospectively be applicable in e.g. 
cancer therapy. Finally, from a researcher’s point of view, it remains interesting to 
unravel the functional reason for the lower protein expression in Tregs as compared 
to Tconv. 
3.2  TCR signaling in Tregs versus Tconv 
Our department recently performed quantitative phosphopeptide sequencing of 
ex vivo isolated murine Tregs and Tconv, both unstimulated and stimulated, to gain 
insights into diverging phosphorylation events at steady state and following activation 
in the two T cell subsets [132]. Due to large amounts of required material a single 
experiment was accomplished, which excluded the possibility to perform kinetics 
following TCR stimulation over time. Therefore, in the thesis in hand, phosphorylation 
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kinetics were addressed via phospho-flow cytometry, which combined the 
advantages of single cell-based analysis, side by side comparison of Tregs and 
Tconv, adequate cell material needs and unproblematic feasibility of kinetics. Poor 
availability of phospho-specific antibodies against molecules and sites of interest 
allowed thorough examination of only one of the previously identified differentially 
regulated phosphorylation-sites, namely CD3ζ pY142 (Fig. 2). It was reported that 
this site shows reduced phosphorylation upon TCR ligation in Tregs as compared to 
Tconv [157]. Interestingly, data from the previously performed phosphoproteome in 
our department depicts drastically elevated phosphorylation of Y142 in resting Tregs 
as compared to Tconv. Upon stimulation, phosphorylation is reduced in Tregs 
whereas in Tconv the phosphorylation level rises (Fig. 2) [132]. None of these 
described phosphorylation phenotypes of CD3ζ pY142 could be detected from the 
phospho-flow cytometry kinetics performed in the study in hand. In line with these 
finding, no changes of phosphorylation level of Lck pY505 and ZAP70 pY319 were 
detected. According to literature, Lck pY505 is expected to be rapidly 
dephosphorylated upon TCR ligation: Lck is constitutively membrane bound and 
located in proximity to the phosphatase CD45 and C-terminal Src kinase (CSK) in 
resting T cells. Interaction with those two enzymes regulates switching of Lck 
between inactive, primed and active state, according to presence and absence of 
phosphogroups at Y534 and Y505. Under steady state, Lck is dephosphorylated at 
Y534 by CD45 and phosphorylated at Y505 by CSK, which keeps Lck in a closed 
conformation (inactive: Y534 pY505). Upon dephosphorylation of Y505, also 
mediated by CD45, Lck structure opens, and the molecule is primed (primed: Y534 
Y505). Auto-transphosphorylation at Y534 by Lck itself, finally results in full activation 
of the kinase, which subsequently enables Lck to phosphorylate the ITAMs of the 
TCR/CD3 complex (active: pY534 Y505) [260]. Amongst the targets of activated Lck 
are the ITAMs located at CD3ζ [261, 262], which in a phosphorylated state serve as 
docking stations for other components of the TCR signalosome such as ZAP70 [263-
267]. Following TCR engagement, ZAP70 is recruited to the plasma membrane and 
directly binds phosphorylated ITAMs. This interaction causes structural 
rearrangements within ZAP70 and phosphorylation of Y319, which in turn recruits Lck 
[268, 269]. By autophosphorylation and via Lck, the amino acid residues, Y492 and 
Y493 of ZAP70, are phosphorylated, which subsequently fully activates ZAP70 [270]. 
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Phosphorylated Y319 therefore stabilizes the active conformation of ZAP70 indirectly 
through recruitment and binding of Lck. Therefore, for the analyzed phosphorylation 
site Y319 in ZAP70, increasing phosphorylation levels following TCR ligation were 
expected, but could not be detected in the present study. Possible explanations, why 
for none of the three examined sites, the expected phosphorylation dynamics could 
be observed, might be inappropriate stimulation or insufficient sensitivity of 
phospho-flow cytometry. Though, inadequate cell activation can be excluded as 
ERK1/2 was phosphorylated both in Tregs and Tconv, and the measured kinetic of 
ERK1/2 phosphorylation also ensures that the observed time frame included 
activation and slow return back to steady state. For ZAP70, differential expression 
levels in Tregs and Tconv following anti-CD3/28 stimulation are described, which 
might blur the comparison of protein phosphorylation within the two T cell subsets 
[64]. Therefore, total expression levels of the respective protein could be determined 
to normalize detected phosphorylation events to the general protein level. However, 
regarding the present study, perturbations of the phosphorylation kinetics by 
differentially regulated gene expression upon stimulation within Tregs as compared to 
Tconv can be excluded, as the observed time frame of 5 minutes is most probably 
too short to severely affect gene expression, protein synthesis or degradation.  
Therefore, phospho-flow cytometry might lack sufficient sensitivity to track minor 
and fast changes of phosphorylation levels in primary T cells upon TCR ligation. 
Alternative methods to analyze early TCR downstream signaling include 
immunoprecipitation steps to enrich signaling complexes of interest and thereby 
reduce amounts of needed cell material. However, this excludes the possibility to 
analyze different cell subsets, such as Tregs and Tconv, side by side from the same 
stimulated sample [271, 272]. Another option to reduce cell amounts but enable 
kinetics of various phosphorylation sites in parallel is mass cytometry. Therefore, this 
method might be a promising alternative to expand our findings from quantitative 
phosphopeptide sequencing. [273]. But also here, Tregs and Tconv would need to be 
separately stimulated and barcode-labeled, and for both suggested methods 
phosphospecific antibodies are urgently required. In summary, although 
phospho-flow cytometry currently belongs to state of the art techniques, there are two 
major obstacles that prevent expansion of knowledge of TCR downstream signaling 
using this method: (i) More flow-suitable phospho-specific antibodies are urgently 
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needed and (ii) sensitivity of flow cytometers need improvement. Advancement of 
techniques in these regards is of utmost importance for immunological research, as 
evidence is accumulating that T cell subset-specific signaling serves as very 
promising target for the development of new therapeutic strategies. 
3.3  The role of CalDAG GEFI in murine T cells 
CalDAG GEFI is known for its role in integrin activation and integrins are 
important for formation and stability of the IS [182, 195, 209, 210]. Therefore, and 
additionally due to the newly identified and differentially regulated 
phosphorylation-site at Y523 in Tregs and Tconv [132], it appeared as promising 
candidate to address IS formation and stability specifically in Tregs. 
3.3.1  Y523 – A novel phosphorylation site at murine CalDAG GEFI 
The functional role of the novel phosphorylation site Y523 is of relevance, as it 
might e.g. regulate subcellular localization or enzymatic activity of CalDAG GEFI 
specifically in Tregs. Thus, characterization of this phosphorylation-site might enable 
identification of molecular targets for specific intervention with IS formation, and 
hence activation, in Tregs.  
As Y523 locates to the C1 domain of CalDAG GEFI it was tempting to speculate 
that the phosphorylation status impacts phorbol ester responsiveness. It was shown 
before that the amino acid composition of CalDAG GEFI C1 domain does not permit 
DAG or PMA binding and interestingly, Johnson and colleagues hypothesized, that 
the inability of CalDAG GEFI to respond to phorbol esters might not solely result from 
the secondary protein structure of the C1 domain [244, 246]. Therefore, as Y523 is 
localized within the DAG binding pouch (Fig. 4e) and a phosphogroup impacts the 
local charge of the protein, we speculated that DAG responsiveness of CalDAG GEFI 
depends on the phosphorylation status of Y523. This hypothesis could not be 
confirmed by the performed membrane lipid PIP strips, at least for the given 
experimental setup in the present study. Although more sensitive and specific 
techniques could be applied to ensure that the phosphorylation status of Y523 is not 
affecting DAG affinity, it appears highly unlikely that CalDAG GEFI is directly 
interacting with phorbol esters. The functional implication of pY523 and its differential 
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regulation in Tregs and Tconv is presumably not related to DAG-mediated subcellular 
localization of CalDAG GEFI.  
To address a possible impact of pY523 on enzymatic activity of CalDAG GEFI, 
pull-down of active Rap1 from stimulated Tregs and Tconv could be employed. 
Differences in Rap1 activation in the two T cell subsets might originate from varying 
enzymatic activity of CalDAG GEFI caused by differential phosphorylation at Y523. 
Of course other cell intrinsic factors influence Rap1 activation, therefore the applied 
experimental system would need to be planed precisely and require e.g. knockout of 
other RapGEFs than CalDAG GEFI to specifically draw conclusions for this molecule. 
It was published that protein kinase A-mediated phosphorylation of CalDAG GEFI at 
S116/117, located within the N-terminal RasGEF domain, interferes with Rap1 
activation [274, 275]. Given the position of Y523 within the protein’s domain structure, 
it is therefore rather unlikely that this phosphorylation-site affects enzymatic function 
of CalDAG GEFI. 
Besides recruitment by phorbol esters and activity regulation, tyrosine 
phosphorylations can serve as docking sites for SH2 domain-containing proteins 
[276]. Therefore, it might be helpful to compare the interactome of phosphorylated 
and unphosphorylated CalDAG GEFI to draw conclusions for the pY523 function. 
Additionally, interaction partners could potentially also explain the responsiveness of 
CalDAG GEFI to PMA stimulation, although the protein cannot directly interact with 
phorbol esters. Interacting proteins could experimentally be identified by combined 
co-immunoprecipitations and mass spectrometry. This experimental setup might also 
allow the identification of the kinase and phosphatase, which are phosphorylating 
and dephosphorylating CalDAG GEFI at Y523, respectively. Plenty of tyrosine 
phosphatases are reported to contribute to TCR downstream signaling, e.g. CD45, 
SHP-1 and SHP-2, PTPN2 and PTPN22 just to name a few [277]. As expected some 
of these phosphatases were also shown to be involved in T cell adhesion processes 
[278, 279]. Accordingly, there are several possible tyrosine kinases which might be 
responsible for pY532. The TEC-family member IL-2-inducible T cell kinase (ITK) 
might be a promising candidate, as it was shown before that mutations in ITK affect 
LFA-1 recruitment following TCR stimulation [280]. Knowledge about the kinases, 
respectively phosphatases that modulate Y523 includes the possibility to identify 
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molecular targets to indirectly impact CalDAG GEFI and downstream signaling in 
Tregs or Tconv. 
Taken together, there is reasonable evidence that CalDAG GEFI localization 
and function are regulated by several phosphorylation events, but the role of pY523 
still needs to be clarified. To achieve that, the most promising option might be the 
identification of interaction partners of phosphorylated and unphosphorylated 
CalDAG GEFI. Generally, functional characterization of phosphorylation-sites serves 
a promising tool for the identification of targets to specifically interfere with signaling 
pathways, and might include the possibility to precisely address certain cell subsets 
in a particular environmental context, such as infection. 
3.3.2  The role of CalDAG GEFI in adhesion and migration of Jurkat T cells 
Adhesion experiments performed in the thesis in hand clearly demonstrated a 
function of CalDAG GEFI in cell adhesion of Jurkat T cells. This applied to fibronectin 
and ICAM-1, which covered β1 integrin- and β2 integrin-dependent adhesion 
processes, respectively. Regarding β1 integrin-mediated adhesion, findings of the 
present study are in contrast to published results: Ghandour et al. postulate no role 
for CalDAG GEFI and Rap1 in very late antigen-4 (VLA-4) activation, the prominent 
fibronectin-binding integrin of T cells [249]. However, there are two major differences 
regarding the experimental setup of the study referred to and the thesis in hand: (i) 
Ghandour and colleagues inhibit Rap1 directly by overexpression of the RapGAP 
Spa-1, which actually bypasses CalDAG GEFI. In the present study, the utilization of 
knockout Jurkat T cells unequivocally showed the impact of CalDAG GEFI deficiency 
on T cell adhesion. (ii) Whereas in the study in hand direct TCR stimulation was 
employed, Ghandour et al. utilized SDF-1α as T cell stimulant. Therefore, differences 
in TCR downstream signaling and chemokine receptor-mediated signaling might also 
account for the observed discrepancy [249]. In summary, we conclude that 
CalDAG GEFI implemented both affinity- and avidity-mediated cell adhesion, 
facilitated by β1 and β2 integrins, respectively. 
Migration behavior of CalDAG GEFI-/- T cells was not investigated so far, but it 
was shown that Rap1 functions in T cell locomotion [224, 281, 282]. GDP-bound 
Rap1 limits T cell rolling on blood vessel endothelium and thereby restrains cells from 
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homing to organs. GTP-bound Rap1 activates LFA-1 and induces T cell arrest on 
high endothelial venules (HEVs) promoting T cell LN homing [224]. In the thesis in 
hand, CalDAG GEFI-/- Jurkat T cells did not display aberrant migration behavior in 
in vitro assays towards SDF-1α. This finding corresponds to results from Ghandour 
et al. who stated no impact of CalDAG GEFI on VLA-4-dependent adhesion upon 
SDF-1α treatment [249]. Therefore, CalDAG GEFI might be dispensable for 
chemokine-induced T cell migration, but implements cell adhesion, triggered by TCR 
stimulation or PMA treatment. As studies regarding neutrophils were conducted 
under inflammatory conditions, also CalDAG GEFI-/- T cells might be challenged in an 
inflammatory or infectious environment to investigate their migration capabilities. 
Additionally, the function of CalDAG GEFI might not only be context- but also 
cell-specific and thus, CalDAG GEFI might be generally dispensable for 
integrin-mediated T cell migration. Another study identifies an integrin-independent 
impact of CalDAG GEFI on neutrophil chemotaxis, involving the actin cytoskeleton, 
especially F-actin distribution, and cell polarization [283]. This finding is particularly 
interesting as an interaction between CalDAG GEFI and F-actin was reported before 
[248]. 
In summary, several studies, including the thesis in hand, have shown a role for 
CalDAG GEFI in cell adhesion of various cell types. Regarding migration processes, 
CalDAG GEFI might be dispensable in T cells. Therefore, CalDAG GEFI might 
support integrin activation at the IS and the differential phosphorylation might affect 
this scenario divergently in Tregs and Tconv. This could e.g. lead to enhanced or 
faster LFA-1 activation in Tregs, resulting in a benefit over Tconv. In terms of 
suppressive activity this advantage would be essential for Tregs to enable e.g. 
down-modulation of costimulatory molecules from the APC surface before Tconv get 
activated. On the other side, CalDAG GEFI-/- Jurkat T cells did not fully abrogate cell 
adhesion, which is probably due to the fact that other RapGEFs compensate for the 
loss of CalDAG GEFI [214-220]. Thus, experimentally it would be very challenging to 
unequivocally show the impact of CalDAG GEFI on IS formation or stability. 
Simultaneous knockout or chemical blockade of redundant RapGEFs would be 
required, which certainly affects cell survival drastically.  
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3.3.3  Phenotypic characterization of murine CalDAG GEFI-/- T cells 
The detected differential phosphorylation at Y523 of CalDAG GEFI attracted our 
attention to the general role of this protein in T cells, especially in Tregs. Although, 
CalDAG GEFI-/- mice were generated more than a decade ago, the T cell 
compartment was not analyzed yet, because Crittenden et al. did not detect 
CalDAG GEFI in murine T cells [237]. CalDAG GEFI-/- mice are fertile and do not 
display any obvious abnormalities, besides slightly extended bleeding times after 
injury due to delayed platelet activation [237, 243]. Flow cytometric analysis of the 
T cell compartment of thymi and SLOs conducted within the present study were in 
line with these findings and did not reveal peculiarities between CalDAG GEFI+/+, 
CalDAG GEFI+/- and CalDAG GEFI-/- mice. A recent publication identifies 
CalDAG GEFII and CalDAG GEFIII (RasGRP1 and RasGRP3, respectively) as 
important molecular players for efficient migration of early thymic progenitors from the 
bone marrow via the blood stream into the thymus [284-286]. Double knockout mice 
for CalDAG GEFII and CalDAG GEFIII display significantly reduced thymocyte 
numbers, which is not due to bone marrow- or thymus-intrinsic aberrations of T cell 
development, but because of impaired CCR9-dependent migration of precursor cells 
from the blood into the thymus [287]. However, the authors did not analyze 
frequencies and absolute numbers of thymocytes after the DN stage. In the thesis in 
hand, CalDAG GEFI-/- mice displayed thymocyte frequencies at expected ratios and 
at unaltered numbers, which also applied to Treg precursors and different maturation 
levels of Tregs and Tconv according to CD24 expression. In line with these findings, 
all analyzed T cell subsets from pooled spleen and LNs appeared comparable in 
CalDAG GEFI+/+, CalDAG GEFI+/- and CalDAG GEFI-/- mice in terms of population 
frequency and absolute numbers. Therefore, CalDAG GEFI expression of murine 
T cells is dispensable for thymic T cell development and T cell homeostasis in 
peripheral lymphoid organs under steady state conditions. 
3.3.4  Signaling properties of murine CalDAG GEFI-/- T cells 
Due to the fact that Rap1 and CalDAG GEFI were shown to be involved in 
signaling networks including ERK1/2 [216, 220, 225, 226, 232], TCR downstream 
signaling events were analyzed in primary murine T cells in the study in hand. 
Analysis of ERK1/2 phosphorylation in Tregs and Tconv from CalDAG GEFI+/+ and 
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CalDAG GEFI-/- mice following TCR stimulation via crosslinked anti-CD3/28 
antibodies did not discover aberrant ERK1/2 phosphorylation. Accordingly, global 
signaling events detected by total tyrosine phosphorylation were found comparable in 
CD4+ T cells from CalDAG GEFI+/+, CalDAG GEFI+/- and CalDAG GEFI-/- mice. 
Therefore, the postulated role for Rap1 in ERK1/2 signaling is most probably not 
mediated via CalDAG GEFI but by another Rap1GEF. Furthermore, the majority of 
studies stating a Rap1/ERK1/2 connection are conducted in cancer cell lines such as 
HEK 293T cells [216, 232] and utilize dominant active mutants of Rap1 or a RapGAP 
[225, 226]. Taking into account the clean experimental system using primary cells 
from knockout and control mice and the direct stimulation of the TCR employed for 
pERK1/2 phospho-flow experiments, there is no evidence from the study in hand that 
CalDAG GEFI is involved in ERK1/2 signaling or TCR downstream signaling in 
general in T cells. As all experiments were performed under steady state conditions, 
this picture might change in an inflammatory or infectious environment. However, 
again the major obstacle remains RapGEFs that act in redundancy to CalDAG GEFI. 
3.3.5  CalDAG GEFI fine-tunes Treg function in vivo 
In order to further study the general role of CalDAG GEFI in Tregs we analyzed 
the suppressive capacity of CalDAG GEFI-/- Tregs in vitro and in vivo. Pre-activated 
Tregs from CalDAG GEFI+/+, CalDAG GEFI+/- and CalDAG GEFI-/- Tregs displayed 
comparable capacity to suppress bead-stimulated proliferation of Tnaive in vitro. 
Consequentially, CalDAG GEFI might be dispensable for Treg suppressive activity or 
the experimental setup covers subtle differences due to the applied pre-activation. 
Directly ex vivo isolated Tregs from CalDAG GEFI+/+, CalDAG GEFI+/- and 
CalDAG GEFI-/- mice were not suppressive at any tested Treg:Tnaive ratio and under 
various tested stimulation conditions (data not shown), which made pre-activation of 
the Tregs necessary. Using the in vivo T cell transfer model of colitis, 
CalDAG GEFI-/- Tregs displayed slightly reduced capacity to rescue inflammation 
severity as compared to CalDAG GEFI+/+ Tregs. The observed phenotype was rather 
mild and only apparent from histology scores of the colons, and interestingly, transfer 
of elevated Treg numbers rescued the slight defect of CalDAG GEFI-/- Tregs. This 
reflects reduced, but not abolished suppression, which might be explained by 
improper IS formation between CalDAG GEFI-/- Tregs and APCs. 
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CalDAG GEFI-/- Tregs might display reduced Rap1 activation, resulting in impaired 
LFA-1 activation and loosened interaction strength between Tregs and APCs. 
Regarding the suppressive modes of Tregs, inappropriate IS formation might impede 
CTLA-4-mediated down-regulation of CD80/86 from APCs [108-111, 288] or might 
affect directed vesicle release from the Tregs towards the APCs [289]. Therefore, the 
observed rescue from colitis by a mere increase of Tregs might be explained by 
utilization of different mechanisms of action of the Tregs, as for example cytokine 
deprivation. To address these possibilities experimentally, reduced activation of Rap1 
and LFA-1 in CalDAG GEFI-/- Tregs could be tested via pull-down of active Rap1 or 
microcopy of the synapse using conformation-specific antibodies against LFA-1. As 
migration of CalDAG GEFI-/- Jurkat T cells was unaffected, it is unlikely that the 
observed phenotype in transfer colitis experiments is due to impaired migration of 
CalDAG GEFI-/- Tregs to the gut. Furthermore, expression of CD103, which is 
needed for T cell retention in the gut [290], was found equivalent on 
CalDAG GEFI-/- and CalDAG GEFI+/+ Tregs. Additionally, if diminished migration 
would be the leading cause, an earlier onset of colitis after co-transfer of 
CalDAG GEFI-/- Tregs as compared to CalDAG GEFI+/+ Tregs would be expected, 
which was not apparent from body weight of the recipient animals. Survival and 
proliferation of CalDAG GEFI-/- Tregs as compared to CalDAG GEFI+/+ Tregs was 
unaffected, as similar T cell frequencies and absolute numbers were observed in 
recipient mice from both experimental groups. Elevated absolute numbers of all 
analyzed T cells populations were observed in siLPLs from CalDAG GEFI-/- Treg 
recipients. However, as this affected effector T cells as well as Tregs, it did not 
influence the development of colitis as compared to CalDAG GEFI+/+ Treg recipient 
mice. 
In conclusion, CalDAG GEFI fine-tunes Treg functional properties in an 
inflammatory environment, but the molecular basis remains elusive. In line with the 
observed adhesion deficit, the impairment of the suppressive capacity of 
CalDAG GEFI-/- Tregs was moderate, which is most probably due to redundant 
RapGEFs in T cells. Finally, CalDAG GEFI certainly plays a role during IS formation 
of T cells, but although the differential phosphorylation at Y523 in Tregs and Tconv 
might lead to distinct protein recruitment or activity, this impact seems to be rather 
minor as knockout of the whole protein did not result in a drastic phenotype. 
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3.4 Concluding remarks 
Undeniably the IS formed between T cells and APCs is of supreme importance 
for proper activation and function of Tconv as well as Tregs, and serves as the main 
structural feature that integrates diverse incoming stimuli and initiates TCR signaling. 
Therefore, and due to the increasing number of studies revealing molecular 
differences in Tregs and Tconv with respect to signaling processes, the IS persists in 
the focus of T cell research. It remains demanding to specifically address differences 
in signaling between Tregs and Tconv, which is due to lack of appropriate tools and 
clean experimental systems. Screening approaches covering transcriptomics, 
proteomics and phosphoproteomics gather hints for potential candidate genes, 
proteins and posttranslational modifications. In the present study, the role of Themis 
and CalDAG GEFI, both candidates identified from screening approaches, were 
investigated with regard to their contribution to the peculiar immunosuppressive 
phenotype of Tregs. For Themis, no specific functional implementation of the 
observed underrepresentation at protein level in Tregs could be found. Regarding 
CalDAG GEFI, a minor involvement in Treg suppressive capacity was identified, 
which probably originates from CalDAG GEFI’s role during IS formation. 
 Besides focusing on certain candidate genes or proteins, the bigger biological 
context should be considered intensely to pinpoint assailable differences between 
Tregs and Tconv. It becomes apparent, that fundamental alterations between Tregs 
and Tconv are not only found at gene or protein level, but rather within specialized 
intracellular signaling networks and processes. Thereby, identical protein inventory 
allows for distinct functional features simply by differentially regulated interplay 
between signaling components in Tregs and Tconv. Up to date, it remains laborious 
to untangle signaling networks, as seen regarding phospho-flow cytometry 
experiments in the present study, but new methods are constantly being developed 
and improved, which will prospectively supply basic research as well as diagnostics 
with appropriate tools. Definitively, signaling processes are promising targets for 
T cell subset- and context-specific manipulation of T cell function. 
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4. Materials and Methods 
4.1  Mouse strains 
Foxp3hCD2Thy1.1+ reporter mice (BALB/c, [291]), Foxp3hCD2Thy1.2+ reporter 
mice (BALB/c, [292]), CalDAG GEFI-/- (129S4-Sv/Jae, [237]) and Rag2-/- (C57BL/6, 
[293]) mice were bred, housed and handled under specific pathogen-free conditions 
at the Helmholtz Centre for Infection Research (Braunschweig, Germany). Mice used 
in in vivo experiments were age- and gender-matched. Animals were handled with 
welfare and care according to regulations of FELASA. All efforts were made to 
minimize suffering and animal experiments were performed according to institutional, 
state, and federal guidelines.  
4.2  Isolation of primary cells  
Mice were euthanized by CO2 asphyxiation and thymus, spleen and LNs 
(mandibular, accessory mandibular, axillary, brachial, inguinal, mesenteric, iliac) were 
rapidly removed and stored in PBS (Gibco) 0.2 % BSA (Sigma Aldrich). Single cell 
suspensions were prepared by meshing of the organs through a 100 µm cell strainer. 
Cells were pelleted by centrifugation at 350 g for 8 min at room temperature (RT) and 
erythrocytes were lysed by incubation in hypo osmotic lysis buffer (0.01 M potassium 
bicarbonate, 0.155 M ammonium chloride, 0.1 mM EDTA, pH 7.5) for 3 min at RT 
with occasional shaking. Lysis was stopped by addition of 10 fold excess of PBS 
0.2 % BSA, cells were filtered again to remove fat and clumped tissue, and cells were 
pelleted as described above. Subsequently, cell suspensions were kept on ice, 
handled with pre-chilled buffers and centrifuged at 4 °C. Cell number was determined 
by manual counting using a Neubauer improved hemocytometer and trypan blue 
(Sigma Aldrich) for discrimination of dead cells, or aided by Accuri flow cytometer 
(BD Biosciences) and propidium iodide (PI, Sigma Aldrich) for exclusion of dead 
cells.  
4.3  Automated magnetic-activated cell sorting (MACS) 
In order to enrich primary cell suspensions from spleen and LNs for CD4+ 
T cells, cell suspensions were incubated with MACS CD4 direct beads (L3T4) 
(Miltenyi Biotech) at a dilution of 1:20 and, after removal of unbound beads by 
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washing with PBS 0.2 % BSA and centrifugation as described before, separated 
aided by AutoMACS Pro (Miltenyi Biotech).  
4.4  Flow cytometry and fluorescence-assisted cell sorting (FACS) 
For flow cytometric analysis of primary murine cells or cell lines such as 
HEK293T and Jurkat T cells, discrimination of dead cells was facilitated by 
LIVE/DEAD Fixable Dead Cell Stain (LD, Invitrogen) prior to surface and intracellular 
staining. For exclusion of dead cells of unfixed samples, PI was added prior to 
acquisition at the flow cytometer. For the sake of cell viability, LD discrimination was 
dispensed during cell sorting as available agents bear certain toxicity after long term 
incubation. Antibodies were titrated prior to experimental use in order to determine 
antibody concentrations with sufficient separation of positive and negative 
populations combined with minimal background staining. Surface staining using 
anti-human CD2 (RPA-2.10), anti-mouse CD3 (17A2), anti-mouse CD4 (RM4-5), 
anti-mouse CD8 (53-6.7), anti-mouse CD24 (M1/69), anti-mouse CD25 (PC61.5), 
anti-mouse CD62L (MEL-14), anti-mouse CD90.1 (Thy1.1, HIS51), anti-mouse 
CD103 (2E7), anti-mouse CD304 (Neuropilin-1, 3E12), anti-mouse CD357 (GITR, 
DTA-1), anti-human CD3 (OKT3), anti-human CD11a (HI111) or anti-human CXCR4 
(12G5), purchased from BioLegend, eBioscience or BD Biosciences, was performed 
in PBS 0.2 % BSA for 15 min on ice protected from light, and unspecific antibody 
binding was prevented by co-incubation with anti-mouse CD16/32 (2.4G2, BioXcell). 
Intracellular staining for anti-mouse Foxp3 (FJK-16S) and anti-mouse CD152 
(CTLA-4, UC10-4B9) (both eBioscience) was carried out employing Foxp3 staining 
kit (eBioscience) according to the manufacturer’s protocol. Unspecific antigens were 
blocked by co-incubation with RatIgG (Dianova) as used intracellular antibodies were 
purified from rat. Data acquisition was performed using LSRII SORP or LSR Fortessa 
equipped with Diva software (BD Biosciences). Cell sorting was performed in the Cell 
Sorting Facility of the HZI on Aria II SORP (BD Biosciences), Aria Ilu (BD 
Biosciences) or MoFlo XDP (Beckman Coulter) with the help of Lothar Gröbe, Maria 
Höxter and Petra Hagendorff. For data analysis FlowJo software (TreeStar) was 
used. 
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4.5  Phospho-flow cytometry (BD Biosciences) 
Cells were isolated from pooled from spleen and LNs and were stained for dead 
cells and subsequently for surface markers CD4 and CD25 or Foxp3hCD2, if reporter 
mice were used, as described. Next, cells were coated with 10 µg/ml biotinylated 
anti-CD3 (145-2C11, BD Biosciences) and 5 µg/ml biotinylated anti-CD28 (37.51, BD 
Biosciences) for 15 min on ice. After removal of unbound antibodies, cells were 
pre-warmed to 37 °C and stimulation was initiated by addition of 10 µg/ml streptavidin 
(Dianova) in Roswell Park Memorial Institute medium (RMPI, Gibco Glutamax) 
complemented with 10 % FCS, 50 U/ml Penicillin, 50 U/ml streptomycin, 25 mM 
HEPES, 1mM sodium pyruvate (all Biochrom AG) and 50 µM β-mercaptoethanol 
(Gibco) (cRPMI). After indicated time points, cells were fixed (Phosflow Lyse/Fix, BD 
Biosciences) and permeabilized (Phosflow Perm Buffer III, BD Biosciences) 
according to the manufacturer’s protocol. Cells were stained intracellularly for total 
ERK1/2, ERK1/2 pT202/pY204, CD3zeta pY142, Lck pY505, ZAP70 pY319 or 
isotype control (all BD Biosciences Phosflow) and Foxp3, if mice were not Foxp3hCD2 
reporter, at 4 °C overnight. Extensive washing removed excess antibodies the 
following day and samples were acquired in PBS 0.2 % BSA. 
4.6  Pre-activation of Tregs 
Tregs were sorted as CD4+CD25+ from pooled spleen and LNs as described 
above and sorted cells were cultured for 72 h on plate-bound anti-CD3/CD28. For 
antibody coating, wells were incubated overnight at 4 °C with 50 µg/ml goat fraction 
to hamster IgG (MP Biomedicals), washed with PBS and subsequently incubated for 
1 h at 4 °C with 1 µg/ml anti-CD3 (145-2C11, BioLegend) and 3 µg/ml anti-CD28 
(37.51, BioLegend). Sorted cells were cultured in cRPMI supplemented with 40 ng/ml 
IL-2 (R&D). 
4.7  Transduction of Tregs 
As described before, CD4+ T cells were enriched via MACS and cultured on 
plate-bound anti-CD3/CD28 (plate coating as described before) for 40 h. For 
transduction, cells were kept on the stimulus, medium was carefully removed and 
replaced by retrovirus. Cells were spin-infected for 60 min at 400 g and 35 °C and 
additionally incubated 5 h at 37 °C, 95 % humidity and 5 % CO2. Afterwards, virus 
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was carefully aspirated and cRPMI was added instead. 72 h after transduction, cells 
were harvested and transduced Tregs were resorted as CD4+Foxp3hCD2+Thy1.1+, 
where Thy1.1 served as reporter for successful transduction. 
4.8  In vitro suppression assay 
Tnaive were sorted as CD4+CD25-CD62Lhigh and PBS washed for Cell TraceTM 
Violet (CTV, Invitrogen) labeling. CTV was utilized at a final concentration of 2 µM 
and cells were stained for 15 min at 37 °C, staining was stopped by 10 fold excess of 
cRPMI. CTV-labeled Tnaive were co-cultured with pre-activated or transduced Tregs 
at indicated ratios in presence of T activator Beads (Life Technologies) at a ratio of 
one bead to two cells. On day 4, proliferation-dependent CTV dilution was 
determined in living Tnaive by flow cytometry. 
4.9  Transfer colitis 
Tregs were sorted as CD4+CD25+ cells and Tnaive as CD4+CD25-CD62Lhigh 
cells from pooled spleen and LNs as described above. Subsequent to sorting, cells 
were washed in PBS and a total of 4x105 cells was injected intraperitoneally into 
Rag2-/- recipient mice in a ratio of 1:2 or 1:4 (Tregs:Tnaive). General health status 
and body weight of recipient mice was monitored biweekly over maximal ten weeks, 
and mice that lost >20 % of initial body weight were sacrificed. Final analysis 
included measurement of colon length, colon histology, spleen weight, total cell count 
of spleen, mLN and pLN (axial, brachial, inguinal) and FACS analysis of lymphocytes 
from spleen, mLN, pLN and small intestine lamina propria (only performed for 
experiments with 1:2 Tregs:Tnaive). Histology analysis was performed by the 
Mousepathology platform at the HZI and the scoring system was developed by Dr. 
Marina Pils. Briefly, colons were rolled into a “Swiss roll”, fixed in 4 % neutrally 
buffered formaldehyde and embedded in paraffin. Approximately 3 µm thick sections 
were stained with hematoxylin/eosin (H&E) according to standard laboratory 
procedures. Slides were evaluated in a randomized and blinded manner and a 
semi-quantitative score was applied for the marker’s severity, lymphocytic invasion, 
epithelial hyperplasia, single cell apoptosis and area involved. Each marker was 
graded from 0-3 and grades for these markers were added up for a total score of 
0-15. 
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4.10  Isolation of small intestine lamina propria lymphocytes (siLPLs) 
Small intestines were taken from stomach exit to origin of the cecum and feces 
were removed. Guts were cut open lengthwise and intensely washed in PBS 2 mM 
EDTA 0.2 % BSA to remove mucus and intraepithelial lymphocytes. Afterwards, guts 
were rinsed in HBSS 0.2 % BSA to completely remove EDTA and organs were cut 
into small pieces. Pieces were digested for 30 min at 37 °C in HBSS 10 % FCS, 
50 U/ml Penicillin, 50 U/ml streptomycin, 25 mM HEPES, 1 mM sodium pyruvate, 
50 µM β-mercaptoethanol supplemented with 0.1 mg/ml DNAseI, 1 mg/ml 
Collagenase D and 0.1 U/ml Dispase (all Roche Diagnostics). The resulting cell 
suspension was filtered through a 100 µm cell strainer and the isolated cells were 
separated via Percoll (Biochrom AG) gradient. Lymphocytes accumulating at the 
interphase were harvested, washed two more times in PBS 0.2 % BSA, counted and 
stained for flow cytometry. 
4.11  Phosphotyrosine analysis 
CD4+ T cells were MACS-enriched from pooled spleen and LNs of 
CalDAG GEFI-/-, CalDAG GEFI+/- and CalDAG GEFI+/+ mice as described before. 
1x106 cells were stimulated in cRPMI supplemented with either 20 ng/ml PMA and 
1 µg/ml ionomycin (iono) or 35 µM sodium pervanadate (all Sigma Aldrich) for 5 min 
at 37 °C. For anti-CD3/CD28 stimulation, cells were stained with 20 µg/ml 
biotinylated anti-CD3 (145-2C11, BD Biosciences) and 10 µg/ml biotinylated 
anti-CD28 (37.51, BD Biosciences), subsequently crosslinking was allowed for 5 min 
by addition of 10 µg/ml streptavidin (Dianova) in cRPMI. As stimulation controls, cells 
were either left on ice or incubated at 37 °C for 5 min in cRPMI. To stop stimulation, 
cells were washed once in ice-cold PBS and cell pellets were lysed for Western Blot 
analysis. 
4.12  Cell lines 
HEK293T cells (DSMZ ACC 635) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Gibco) supplemented with 10 % FCS, 50 U/ml Penicillin, 50 U/ml 
streptomycin, 25 mM HEPES and 1 mM sodium pyruvate (all Biochrom AG) at 37 °C, 
95 % humidity and 5 % CO2. In order to passage or seed cells, cells were carefully 
rinsed with PBS and treated with 0.5 % Trypsin-EDTA (Gibco) for up to 5 min at 
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37 °C. Detachment of cells was stopped by 10 fold excess of cDMEM. Jurkat T cells 
(clone JE6, gift from Dr. Stefanie Kliche, OvGU, Magdeburg) were cultured in RPMI 
complemented with 10 % FCS at 37 °C, 95 % humidity and 5 % CO2. Cells were 
counted using a Neubauer improved hemocytometer and trypan blue for live/dead 
discrimination. 
4.13  Production of lentiviral and retroviral particles 
Retroviral and lentiviral particles were produced using HEK293T cells seeded in 
19 cm2 culture dishes with 1x106 cells/dish in 3 ml cDMEM. The following day, cells 
were transfected utilizing calcium chloride precipitation. For retrovirus production, 
3 μg of the empty expression vector MSCV_Thy1.1 or MSCV_Thy1.1 containing 
murine Themis (Addgene plasmid #17442, [294]) and 3 μg pCL Eco helper plasmid 
(encoding gag, pol and env, Addgene plasmid #12371, [295]) were used. For 
lentiviral production 5 µg pRRL.PPT.SF.newMCS.i2.EGFP (empty vector or vector 
containing human CalDAG GEFI, modified from pRRL.PPT.SF.IRES.EGFP.PRE, 
[296]), 12 µg pcDNA3.HIV1GP, 5 µg pRSV Rev and 1.5 µg pMD2G plasmid ( all 
plasmids were gifted from Dr. Melanie Galla, MHH, Hannover) were utilized. 
Respective plasmids were mixed with 30 μl 2 M CaCl2 and filled to 250 μl with sterile 
water. This mixture was dripped into 250 μl 2x HBS buffer (280 mM sodium chloride, 
50 mM HEPES, 12 mM D-glucose, 10 mM potassium chloride, 1.5 mM disodium 
phosphate, pH 7.05) or 2x phosphate buffer (280 mM sodium chloride, 50 mM 
HEPES, 1.5 mM disodium hydrogen phosphate), for retrovirus and lentivirus 
production respectively, under vigorous mixing. 500 μl of this transfection solution 
was added immediately to each dish in a drop-wise manner. Cells were incubated 
with transfection solution for 16 h, then medium was exchanged and virus production 
was allowed. Virus supernatant (VSN) was collected the following day and filtered 
through a 0.45 μm strainer to remove detached HEK293T cells. VSN was 
concentrated by overnight centrifugation at 2755 g and 4 °C, and subsequently VSN 
volume was carefully reduced according to the experimental need.  
4.14  CRISPR/Cas9-mediated gene knock-out in Jurkat T cells 
SgRNAs targeting CalDAG GEFI in Jurkat T cells were generated utilizing the 
online tool http://crispr.mit.edu/ (Zhang Lab, MIT, 2015). Selected sgRNAs (see 
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Table 1, page 79) were cloned into pX458 (pSpCas9(BB)-2A-GFP, Addgene plasmid 
#48138, [297]) via BbsI restriction site. Jurkat T cells were electroporated employing 
the Amaxa Cell Line Nucleofector V Kit and the Amaxa Nucleofector device using 
program X-005 according to the manufacturer’s protocol. 48 h after nucleofection, 
single Jurkat T cells were sorted into 96-well round bottom plates according to GFP 
expression using BD FACS Aria II SORP. Single cell clones were expanded and 
tested for CalDAG GEFI expression via Western Blot and a second round of single 
cell sorting was applied to promising clones. Both clones examined in this study, 
namely 1E8_2D5 (clone #1) and 1E8_3D6 (clone #2), were derived from sgRNA#1 
and clone 1E8 generated by the first single cell sorting. Successful knockout of 
CalDAG GEFI was confirmed by repetitive Western Blot analysis and sequencing of 
the genomic DNA of exon 1, subcloned into pCRTM4-TOPO® (Thermo Fisher 
Scientific). 
4.15  Transduction of Jurkat T cells 
Re-expression of CalDAG GEFI in CalDAG GEFI-/- Jurkat T cell clones was 
facilitated by lentiviral transduction utilizing pRRL.PPT.SF.IRES.EGFP.newMCS 
(primer for subcloning see Table 1, page 79). Lentivirus particles were produced 
employing HEK293T cells as described in section 4.13. For transduction, 2x106 
Jurkat T cells were resuspended in 2 ml of concentrated VSN and spin-infected for 
30 min at 800 g. VSN was aspirated and Jurkat T cells were cultured for 72 h in 
RPMI with 10 % FCS before functional assays were performed. Efficiency of 
HEK293T cell transfection and Jurkat T cell transduction was determined via GFP 
expression of HEK293T and Jurkat T cells, respectively. 
4.16  Adhesion and migration assays 
One day prior to the experiment, WT or CalDAG GEFI-/- Jurkat T cells were 
adjusted to 1x105 cells/ml in RPMI with 10 % FCS. Cell adhesion was assessed by 
cell stimulation with 5 µg/ml anti-CD3 (OKT3, BD Biosciences), 50 ng/ml PMA 
(Calbiochem), or 1 mM MnCl2 (Sigma Aldrich) for 30 min at 37 °C. Adhesion on 
Fc-ICAM-1-coated (0.5 µg/well, R&D system) or Fibronectin-coated (1 µg/well, 
Roche) 96-well flat-bottom plates was allowed for 30 min at 37 °C and unbound cells 
were removed by gently washing three times with HBSS (Biochrom AG). The bound 
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cell fraction was determined by counting using an ocular reticle and bound cells were 
calculated as ‚% of input’ in duplicates (2x105 cells seeded initially). Migration 
behavior was analyzed using 5 µm polycarbonate filter transwells (Costar) coated 
with 20 µg/ml fibronectin (1 h at 37 °C, Roche). The lower transwell chamber 
contained either migration assay medium (RPMI, 1 % bovine serum albumin fraction 
V, 10 mM HEPES pH 7.4) or migration assay medium supplemented with 200 ng/ml 
human SDF-1α (BioLegend). 2x105 cells in 200 µl migration assay medium were 
transferred to the upper chamber and after 2.5 h at 37 °C the number of migrated 
cells into the lower chamber was counted. Adhesion and migration assays were 
performed by Dr. Stefanie Kliche (OvGU, Magdeburg). 
4.17  Western Blot 
Primary T cells or Jurkat T cells were lysed in RIPA lysis buffer (50 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 0.5 % sodium deoxycholate, 1 % NP40, 0.1 mM PMSF, 
Roche Complete Mini Protease Inhibitor) and BCA assay (Thermo Fisher Scientific) 
was utilized according to the manufacturer’s instructions to determine total protein 
concentration. Proteins were denatured by incubation in reducing sample buffer 
(50 mM Tris pH 6.8, 50 % v/v glycerol, 10 % w/v SDS, 25 % v/v β-mercaptoethanol, 
0.25 mg/ml bromphenol blue) for 5 min at 95 °C and subsequently separated 
according to protein size using 12 % SDS gels. Proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes employing a “Criterion” blotter (BioRad) 
and transfer buffer (25 mM Tris pH 8.0, 192 mM glycerol, 20 % v/v methanol). After 
protein transfer, PVDF membranes were blocked using blotting-grade milk powder, 
5 % in TBST (137 mM sodium chloride, 2.68 mM potassium chloride, 24.76 mM Tris, 
0.1 % v/v Tween20, pH 7.8), and specific protein bands were detected via 
anti-Rasgrp2 (GTX108616, Genetex), anti-β-actin (AC-74, Sigma) or 
anti-phosphotyrosine (4G10, Upstate) with secondary antibodies anti-rabbit IgG-HRP, 
anti-mouse IgG2a-HRP or anti-mouse IgG2b-HRP (all Southern Biotech). Western 
Blots were developed using Super Signal West Dura Extended Duration Substrate 
(Thermo Fisher Scientific) and Amersham HyperfilmTM ECL (GE Healthcare). 
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4.18  Protein expression, purification and lipid binding assay 
The coding sequence of the C1 domain of murine CalDAG GEFI (corresponding 
to amino acids 495-553) was amplified by Phusion Flash II DNA polymerase (Thermo 
Fisher Scientific) and the PCR product was digested with EcoRI/XhoI and subcloned 
into pGEX-4T-1 (Amersham Bioscience), which concomitantly enabled fusion to a 
GST-tag (primer see Table 1, page 79). The final construct was verified by 
sequencing. Phosphomutant C1 domain constructs were generated employing the 
Q5® Site-Directed Mutagenesis Kit (NEB) following the manufacturer’s protocol 
(primer see Table 1, page 79). For recombinant expression, the respective plasmids 
were transformed into E. coli BL21 and expression was induced using 1 mM 
isopropylthio-β-galactoside at an optical density of 0.7 - 0.9 at 600 nm. Bacteria were 
lysed, recombinant proteins were purified using GSH-columns and dialyzed against 
PBS or PBS supplemented with 100 µM ZnCl2. Expression and purification of 
recombinant proteins was performed at the Free University Berlin in the laboratory of 
Prof. Christian Freund (FU Berlin). To ensure equal protein input to lipid binding 
assays, recombinant protein concentration was determined via BCA assay, and 
0.5 µg/ml of each protein was applied to membrane lipid PIP Strips (Echelon) 
following the manufacturer’s instructions. 
4.19  Statistical analysis 
Graphs and statistics were generated utilizing Prism software (GraphPad). Each 
data point in scatter plots of in vivo experiments represents an individual mouse. If 
not stated otherwise, data are represented as mean±SD. Statistical significance was 
determined via Mann-Whitney test or One-way ANOVA (Bonferroni’s multiple 
comparisons test or Kruskal-Wallis with Dunn’s test for multiple comparisons). * p < 
0.05 was considered significant with * p < 0.05, ** p < 0.01, *** p < 0.001. 
Table 1: Oligonucleotides and primer 
Name Direction Restriction 
site 
Sequence 5’ 3’ Purpose 
sg_hRasgrp2_1_f forward BbsI CACCGGGGTTCGGTCCGA
GCCCGGT 
sgRNA#1 targeting human 
CalDAG GEFI 
sg_hRasgrp2_1_r reverse BbsI AAACACCGGGCTCGGACC
GAACCC 
sgRNA#1 targeting human 
CalDAG GEFI 
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Name Direction Restriction 
site 
Sequence 5’ 3’ Purpose 
sg_hRasgrp2_2_f forward BbsI CACCGTGTACCAGGGGTG
CATCATG 
sgRNA#2 targeting human 
CalDAG GEFI 
sg_hRasgrp2_2_r reverse BbsI AAACCATGATGCACCCCTG
GTACA 
sgRNA#2 targeting human 
CalDAG GEFI 
sg_hRasgrp2_3_f forward BbsI CACCGAGTTGTCCTTCCGG
GATTGT 
sgRNA#3 targeting human 
CalDAG GEFI 
sg_hRasgrp2_3_r reverse BbsI AAACACAATCCCGGAAGGA
CAACT 
sgRNA#3 targeting human 
CalDAG GEFI 
sg_hRasgrp2_4_f forward BbsI CACCGGCAGGTGAAAACG
TGCCACC 
sgRNA#4 targeting human 
CalDAG GEFI 
sg_hRasgrp2_4_r reverse BbsI AAACGGTGGCACGTTTTCA
CCTGC 
sgRNA#4 targeting human 
CalDAG GEFI 
sg_hRasgrp2_5_f forward BbsI CACCGGGGTTCAAGTCAAA
CTCCGC 
sgRNA#5 targeting human 
CalDAG GEFI 
sg_hRasgrp2_5_r reverse BbsI AAACGCGGAGTTTGACTTG
AACCC 
sgRNA#5 targeting human 
CalDAG GEFI 
seq_pX458_U6_fwd forward none GAGGGCCTATTTCCCATGA
TTCC 
Sequencing of pX458 
Gen_J_sg1b_fwd forward HindIII AAGCTTCAGGACGCCTGG
GTTCTC 
Amplify exon 1 of human 
CalDAG GEFI for sequencing 
Gen_J_sg1b_rev reverse XhoI CTCGAGGGCTAGAGAAGG
GAAACCTCATC 
Amplify exon 1 of human 
CalDAG GEFI for sequencing 
T7 primer forward none TAATACGACTCACTATAGG
G 
Sequencing of pCR
TM
4-TOPO
®
 
mRasgrp_C1_fwd forward EcoRI GAATTCATGGGCTTCGTAC
ACAACTTC 
Cloning of murine CalDAG GEFI 
C1 domain into pGEX-4T-1 
mRasgrp_C1_rev reverse XhoI CTCGAGCTGGGCCCTGCG
GCGACA 
Cloning of murine CalDAG GEFI 
C1 domain into pGEX-4T-1 
SDM_Y523F_fwd forward none CTGGGCATCTTCAAGCAGG
GC 
Site directed mutagenesis of 
murine CalDAG GEFI C1 domain 
Y523F 
SDM_Y523F_rev reverse none GATCAGAGCTTTGCAGTGG Site directed mutagenesis of 
murine CalDAG GEFI C1 domain 
Y523F 
SDM_Y523D_fwd forward none CCTGGGCATCGACAAGCA
GGG 
Site directed mutagenesis of 
murine CalDAG GEFI C1 domain 
Y523D 
SDM_Y523D_rev reverse none ATCAGAGCTTTGCAGTGGC Site directed mutagenesis of 
murine CalDAG GEFI C1 domain 
Y523D 
seq_pGEX4_fwd forward none CGACTCGAGCGGCCGCAT
C 
Sequencing of pGEX-4T-1 
seq_pGEX4_rev reverse none CCGGGAGCTGCATGTGTC
AGAGG 
Sequencing of pGEX-4T-1 
cpRRL_hGRP2_fwd forward AscI GGCGCGCCCATGGCAGGC
ACCCTG 
Cloning of human CalDAG GEFI 
into 
pRRL.PPT.SF.newMCS.i2.EGFP 
cpRRL_hGRP2_rev reverse XbaI GGCGCGCCCATGGCAGGC
ACCCTG 
Cloning of human CalDAG GEFI 
into 
pRRL.PPT.SF.newMCS.i2.EGFP 
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Supplementary Information 
 
Suppl. Fig. 1: Absolute numbers of thymic T cell subsets from CalDAG GEFI
+/+
, 
CalDAG GEFI
+/- 
and CalDAG GEFI
-/-
 mice. Single cell suspensions from thymi from CalDAG GEFI
+/+ 
(WT) CalDAG GEFI
+/- 
(HET) and CalDAG GEFI
-/-
 (KO) mice were counted using Accuri flow cytometer 
and analyzed for the depicted markers by flow cytometry (see Fig. 15). Absolute numbers of the 
indicated populations were calculated according to total cell count and population frequency. (A) 
Thymic T cell development was addressed via staining for CD4, CD8 and Foxp3 amongst CD4SP 
thymocytes. (B) The CD4SP compartment was analyzed for CD25
-
Foxp3
-
 Tconv, the Treg precursors 
CD25
+
Foxp3
-
 and CD25
-
Foxp3
+
 as well as CD25
+
Foxp3
+
 Tregs. (C) Maturation stages of 
Foxp3
-
 (upper panel) and Foxp3
+
 (lower panel) were examined according to CD24 expression. Mean 
of each group is depicted and each data point represents an individual mouse (n=6-16). Data are 
pooled from ten independent experiments. 
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Suppl. Fig. 2: Absolute numbers of splenic T cell subsets from CalDAG GEFI
+/+
, 
CalDAG GEFI
+/- 
and CalDAG GEFI
-/-
 mice. Single cell suspensions from spleens from 
CalDAG GEFI
+/+ 
(WT) CalDAG GEFI
+/- 
(HET) and CalDAG GEFI
-/-
 (KO) mice were counted using 
Accuri flow cytometer and analyzed for the depicted markers by flow cytometry (see Fig. 16). Absolute 
cell numbers of the indicated populations were calculated according to total cell count and population 
frequency. Mean is depicted per group and each data point represents an individual mouse (n=6-13 
mice per group). Data are pooled from ten independent experiments. 
 
 
Suppl. Fig. 3: Absolute numbers of splenic T cell subsets from transfer colitis experiments with 
Tregs:Tnaive at a ratio of 1:4. Single cell suspensions from spleens from Rag2
-/-
 recipient mice 
transferred with Tnaive plus CalDAG GEFI
+/+
 (WT) or plus CalDAG GEFI
-/-
 (KO) Tregs were counted 
using Accuri flow cytometer and analyzed for the indicated markers by flow cytometry (see Fig. 21). 
Absolute cell numbers of the indicated populations were calculated according to total cell count and 
population frequency. Data are pooled from two independent experiments, mean is depicted per group 
and each data point represents an individual mouse (n=10 mice per group). 
 
 
 
Supplementary Information 
84 
 
 
Suppl. Fig. 4: Absolute numbers of splenic T cell subsets from transfer colitis experiments with 
Tregs:Tnaive at a ratio of 1:2. Single cell suspensions from spleens from Rag2
-/-
 recipient mice 
transferred with Tnaive plus CalDAG GEFI
+/+
 (WT) or plus CalDAG GEFI
-/-
 (KO) Tregs were counted 
using Accuri flow cytometer and analyzed for the indicated markers by flow cytometry (see Fig. 23). 
Absolute cell numbers of the indicated populations were calculated according to total cell count and 
population frequency. Data are pooled from two independent experiments, mean is depicted for each 
group and each data point represents an individual mouse (n=9-10 mice per group). 
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Abbreviations 
129S4-Sv/Jae Steel group of 129 substrains, (inbred mouse strain) 
ADAP   Adhesion and degranulation promoting adaptor protein 
Aire   Autoimmune regulator 
AKT   Protein kinase B 
AP-1   Activator protein 1 
APC   Antigen presenting cell 
BALB/c   Bagg albino (inbred mouse strain) 
BCA   Bicinchoninic acid 
BCR   B cell receptor    
Breg   Regulatory B cell 
BSA   Bovine serum albumin 
C1   conserved region 1 
C3G   CRK-SH3 domain binding GEF 
C57BL/6    inbred mouse strain, black fur 
CABIT   Cysteine-containing all beta in Themis 
CalDAG GEFI Ca
2+
 and DAG regulated guanine nucleotide exchange factor I, GRP2 
cAMP   Cyclic adenosine monophosphate 
Cas9   CRISPR-associated protein 9 (nuclease) 
CCR   C-C chemokine receptor 
CD   Cluster of differentiation 
CD11a   Integrin αL 
CD18   Integrin β2 
CD103   Integrin αE 
CD4SP   CD4 single positive (CD4
+
CD8
-
) 
CD8SP   CD8 single positive (CD4
-
CD8
+
) 
Cdc25   Cell division control protein 25 
Cdc42   Cell division control protein 42 
CDM C. elegans Ced-5, mammalian Dock180 and D. melanogaster myoblast city 
Clone #1/#2 CalDAG GEFI
-/-
 Jurkat T cell clones, 1E8_2D5 and 1E8_3D6 
CNS   Conserved non-coding sequence 
CRISPR   Clustered regularly interspaced short palindromic repeats 
CSK   C-terminal Src kinase 
cSMAC   Central SMAC 
CTL   Cytotoxic T lymphocyte 
CTLA-4   Cytotoxic T lymphocyte-associated antigen-4, CD152 
CTV   Cell Trace
TM
 Violet 
CXCR4   C-X-C chemokine receptor type 4 
DAG   Diacylglycerol 
DC   Dendritic cell 
Dlgh1   Disc large homologue 1 
DMEM   Dulbecco’s modified Eagles medium 
DN   Double negative (CD4
-
CD8
-
) 
DNase   Deoxyribonuclease 
Abbreviations 
106 
 
Dock4   Dedicator of cytokinesis protein 4 
DP   Double positive (CD4
+
CD8
+
) 
dSMAC   Distal SMAC 
ECL   Enhanced chemiluminescence 
E. coli   Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
EF-hand Ca
2+
-binding motif composed of two helices (E and F) joined by a loop 
Elk1   Ets-domain-containing protein 
Epac   Exchange factor directly activated by cAMP 
ERK   Extracellular signal-regulated kinase 
F-actin   Filamentous actin 
FACS   Fluorescence-activated cell sorting 
Fc   Fragment constant 
FCS   Fetal calf serum 
FMO   Fluorescence minus one 
Foxp3   Forkhead box protein 3 
GAP   GTPase activating protein 
Gata-3   Trans-acting T cell-specific transcription factor 
GDP   Guanosine diphosphate 
GEF   Guanine exchange factor 
Geomean  Geometric mean fluorescence intensity 
GFP   Green fluorescent protein 
GITR   Glucocorticoid-induced TNFR-related protein, CD357 
GRB2   Growth factor receptor bound protein 2 
GST   Glutathion-S-transferase 
GTP   Guanosine triphosphate 
GTPase   Guanosine triphosphatase 
GzmA   Granzyme A 
GzmB   Granzyme B 
HBS   HEPES buffered saline 
HBSS   Hank’s buffered saline solution 
hCD   Human CD 
H&E   Hematoxylin & Eosin 
HEK293T  Human embryonic kidney cells 
HEPES   N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
HEV   High endothelial venules 
HSC   hematopoietic stem cell 
HRP   Horse radish peroxidase 
ICAM-1   Intercellular adhesion molecule-1 
ICOS   Inducible costimulator 
IDO   Indoleamine (2,3)-dioxygenase 1 
IFNγ   Interferon gamma 
IgG   Immunoglobulin G 
IL   Interleukin 
Iono   Ionomycin 
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IP3   Inositol (1,4,5)-trisphosphate 
IPEX Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome 
IS   Immunological synapse 
ITAM   Immune-receptor tyrosine-based activation motif 
ITK   IL-2 inducible T cell kinase 
iTRAQ   Isobaric tags for relative and absolute quantitation 
JE6   Jurkat clone E6 
kDa   kilo Dalton 
KO   Knockout 
LADIII   Leukocyte adhesion deficiency type III 
LAG-3   Lymphocyte activation gene 3 
LAT   Linker for activation of T cells 
LC-MS/MS  Liquid chromatography–mass spectrometry/ mass spectrometry 
Lck   Lymphocyte cell-specific protein tyrosine kinase 
LD   Live/Dead 
LFA-1   Lymphocyte function-associated antigen-1 
LN   Lymph node 
MACS   Magnetic-activated cell sorting 
MDSC   Myeloid-derived suppressor cell 
MELC   Multi epitope ligand cartography 
MEK   Mitogen-activated protein ERK kinase 
MHC   Major histocompatibility complex 
mLN   Mesenteric LN 
NFAT   Nuclear factor of activated T cells 
NFκB   Nuclear factor „kappa-light-chain-enhancer“ of activated B cells 
NK cell   Natural killer cell 
Nrp1   Neuropilin-1, CD304 
ns   not significant 
PAMP   Pathogen-associated molecular pattern 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PD-1   Programmed death-1, CD279 
PDZ   PSD-95, DLG and ZO-1  
PI   Propidium iodide 
pERK   Phosphorylated ERK   
PIP3   Phosphatidylinositol (3,4,5)-triphosphate 
PKCθ   Protein kinase C theta 
pLN   Peripheral LN 
PLCγ1   Phospholipase C gamma 1 
PMA   Phorbol 12-myristate 13-acetate 
pMHC   Peptide-loaded major histocompatibility complex 
PRR   Pattern recognition receptor 
pS   Phosphorylated serine 
pSMAC   Peripheral SMAC 
pT   Phosphorylated threonine 
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pTregs   Peripherally-induced Tregs 
PVDF   Polyvinylidene difluoride 
pY   Phosphorylated tyrosine 
Raf   Rat fibrosarcoma 
Rag   Recombination activating gene 
Rap1   Ras-related protein 1 
RapL Regulator for cell adhesion and polarization enriched in lymphoid tissues 
Ras   Rat sarcoma 
REM   Ras exchange motif 
RhoH   Rho-related GTP-binding protein H 
RIAM   Rap1-GTP-interacting adapter protein 
RIPA   Radioimmunoprecipitation assay 
RORγt   RAR-related orphan receptor gamma 
ROS   Reactive oxygen species 
RPMI   Roswell Park Memorial Institute 
RT   Room temperature 
SD   Standard deviation 
SDF-1α   Stromal cell-derived factor-1, CXCL12 
SDS   Sodium dodecyl sulfate 
SFFV   Spleen Focus Forming Virus 
sgRNA   Single guide RNA 
SH2   Src homology 2 
SHARPIN  SHANK-associated RH domain interactor 
SHP-1   Tyrosine-protein phosphatase non-receptor type 6, PTPN6 
SHP-2   Tyrosine-protein phosphatase non-receptor type 11, PTPN11 
siLPL   Small intestine lamina propria lymphocyte 
siRNA   Small interfering RNA 
SKAP-55   Scr kinase-associated phosphoprotein of 55 kDa 
SLO   Secondary lymphoid organ 
SLP-76   SH2 domain-containing leukocyte protein of 76 kDa 
SMAC   Supramolecular activation cluster 
SOS1   Son of sevenless homologue 1 
Spa-1   Signal-induced proliferation-associated protein 1 
T-bet   T-box transcription factor 21, TBX21 
TBST   Tris buffered saline supplemented with Tween 20 
TCF7   Transcription factor 7 
Tconv   Conventional T cells 
TCR   T cell receptor 
TEC   Transient erythroblastopenia of childhood 
TGF-β   Transforming growth factor beta 
Th   Helper T cell 
Themis   Thymocyte-expressed molecule involved in selection 
Themis-tg Transgenic mice expressing Themis under the control of the hCD2 promoter 
Thy1.1   Thymus cell antigen 1, CD90.1 
Tnaive   Naïve T cell 
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Tregs   Regulatory T cells 
TSDR   Treg-specific demethylated region 
tTregs   Thymic-induced Tregs 
unstim   unstimulated 
VLA-4   Very late antigen-4 
VSN   Virus supernatant 
WT   Wild type 
ZAP70   70 kDA zeta-chain associated protein 
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